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Abstract 
Breaking the Chain:  
Evaluating the Links Between Opioid Use Disorder, Overdose, and Suicide  
Amanda Nicole Stover 
   
Previous research has estimated that 20–30% of individuals with opioid use disorder 
(OUD) have a history of both suicide attempt and unintentional opioid overdose. In 2018, more 
than 1.9 million adults 18 years and older had an OUD; while 1.4 million adults attempted 
suicide that same year (SAMHSA, 2019). The key to understanding this relationship is 
examining behaviors that precede these potentially fatal behaviors. One such precursory behavior 
is self-injury. Self-injurious behaviors (SIB) are one of the most important risk factors for future 
suicide (Cavanagh et al.,2003). Among individuals with OUD, previous research has found that 
those with OUD and SIB have a standardized mortality ratio approximately 14 times greater than 
those without OUD (Darke & Ross, 2002; Harris & Barraclough, 1997; Tremeau et al., 2008; 
Wilcox et al., 2004).  
This study has three primary objectives. The first is to conduct a systematic literature 
review to better understand the relationship between SIB, overdose and/or suicidal behaviors (i.e. 
suicidal ideation, suicide planning, or attempt) among people with OUD. The literature search 
was conducted in accordance with PRISMA guidelines for systematic reviews and meta-
analyses. Forty-seven studies were included that examined the relationship between overdose, 
SIB, and/or suicidal behavior among people with OUD. Of these studies 46 were assessed using 
the NHLBI quality tool, 17.4% of studies were rated as poor, 32.6% were rated as fair, and 
50.0% of studies were rated as good. Seven common themes were identified including: patterns 
 
of substance use, psychological factors/diagnoses, sociodemographic characteristics, family 
history, traumatic life events, gender, and methods of suicide attempt. In general, patients with 
OUD who are at highest risk of suicide attempt and SIB tend to have more severe psychiatric 
profiles, increased rates of poly-drug use, tend to be female, experience significant life stressors 
and childhood maltreatment.  
Results from the systematic review were used to inform the second and third aims of this 
study. The second aim was to evaluate the feasibility of a standardized screen for suicide and 
overdose among patients receiving addiction treatment. This was executed by conducting a 
cross-sectional study among a convenience sample of patients (n=113) recruited from two 
inpatient treatment programs. A modified version of the Patient Safety Screener (mPSS) was 
used to screen for suicidal ideation, suicide attempt, and overdose. The screen was administered 
in-person during treatment and administrative clinical data were extracted. Subjects (n=108) and 
members of their clinical care team (n=20) completed a screening acceptability survey. 
Approximately 60% of subjects had a positive mPSS screen, and 30.3% reported having suicidal 
ideation, suicide attempt, and overdose. Both subjects and clinical staff reported that it was 
acceptable to screen for suicide attempt(s) and overdose(s); however, a minority of clinical staff 
reported concerns about administration time (n=7) and impact on workflow (n=6). 
 The combined results of the systematic review and mPSS helped shape the final aim of 
this study. A cross-sectional study conducted in a subset of subjects who screened positive on the 
mPSS were used to assess clinical characteristics. Participants were categorized into three 
mutually exclusive groups: 1) unintentional overdose(s) (OD), 2) suicidal ideation or suicide 
attempt(s) (SI/SA), and 3) suicidal ideation or suicide attempt and unintentional overdose 
(SI/SA/OD). Multinomial logistic regression models were used to determine whether adverse 
 
childhood experiences (ACE), self-injurious behaviors, substance use history, overdose history, 
and past year stressful life events were differentially associated with history of OD/SI/SA. All 
subjects categorized as having an unintentional OD only, reported having ever used cocaine, 
while only 72% of SI/SA subjects had ever used cocaine (p=0.02). Subjects in the unintentional 
OD group were more likely to have used heroin in the 24-hours preceding their most recent 
overdose (92.3%) compared to SI/SA (30.7%) and SI/SA/OD (75.0 %). In the multivariable 
model subjects with history of SI/SA had higher ACE scores and higher mean episodes of SIB 
than either of the other two participant groups.  
Findings from this study support simultaneously screening for suicide and overdose in 
OUD inpatient treatment settings. Yet, upon further assessment of clinical and behavior 
characteristics, history of unintentional OD is distinct from SI/SA. Among patients who screen 
positive for all three outcomes, SI/SA/OD, there appears to be greater clinical severity. 
Therefore, it is important to evaluate patient history of suicidal ideation, suicide attempt(s), and 
overdose(s). More thorough evaluation of drugs involved in overdose and history of self-injury 
may help distinguish future risk and better inform treatment planning. Collectively this 
information has implications for resource needs, treatment, and prevention. However, additional 
research is needed to determine whether screening improves provision of services and reduces 
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1.1 Background and Need for Study 
Premature mortality associated with opioid-related overdose and suicide is a significant 
public health problem in the United States. In 2017, there were 47,600 opioid-related overdoses 
(14.9 per 100,000) and 47,173 (14.0 per 100,000) suicides reported in the U.S. (Hedegaard et al., 
2018; Scholl et al.,2019; SAMHSA, 2019). Previous literature has found that people with OUD 
have a nearly fifteen times greater risk of all-cause mortality than demographically matched 
controls, with overdose being the leading cause of death (Degenhardt, et al., 2010). However, for 
every overdose resulting in death, there are many more nonfatal overdoses. Likewise, having one 
overdose substantially increases the risk of repeat overdose (Larochelle et al., 2016; Hasegawa et 
al., 2014) and markedly elevates short-term risks of mortality (Kelty and Hulse, 2017; Stoove et 
al., 2009). One study, in a cohort of Austrian opioid users, found that following an overdose, 
people with OUD were nearly 50 times more likely to die than matched community controls, 
with most of the deaths involving an opioid (Risser et al., 2001). However, disentangling the 
complex relationship between intentional and unintentional overdoses, even among those 
overdoses that are nonfatal, remains difficult. In this context, repeated overdoses could be further 
complicated by history of self-injury, mental health diagnoses, and other life stressors. 
Understanding the relationship between overdose and suicide may best be explained by 
examining key behaviors that precede these events. Approximately 50–60% of people who die 
by suicide have a documented prior history of self-injurious behavior (SIB) (Foster et al., 1997) 
with many instances of SIB occurring shortly before their fatal act (Gairin et al., 2003). 
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However, a majority of research studies conducted on SIB utilize adolescent samples, with far 
fewer studies focusing on adult populations under the assumption that these behaviors decrease 
in adulthood (Plener et al., 2016). Yet, previous research found individuals with SUDs have a 
10-46% prevalence of SIB compared to 2-4% reported for the general population (Cummings et 
al., 2006; Evren & Evren, 2005; Harned et al., 2010; Maloney et al., 2010). Episodes of SIB are 
one of the most important risk factors for future suicide (Cavanagh et al.,2003). Still, limited 
information is available, specifically with regard SIB and future risk for death by suicide, 
particularly with regard to the prevalence and relationship of lifetime SIB (O’Connor et al., 
2016). 
The relationship between overdose, suicide, and SIB is further complicated by co-
occurring mental health diagnoses. In 2018, individuals with any mental health diagnosis are 
substantially more likely to misuse opioids in the past year than individuals without any 
comorbid mental health diagnosis (SAMSHA, 2019). According to the 2018 National Survey of 
Drug Use and Health, adults with a diagnosis of any mental illness were 9.2% more likely to 
have past year opioid misuse, and adults with a serious mental illness were 14.6% more likely to 
have past year opioid misuse; as compared to the 2.6% of the US population over 18 years old 
with past year opioid misuse and no co-occurring mental health diagnosis (SAMSHA, 2019). 
Studies consistently reported that depression scores were consistently higher, or history of major 
depressive episode was present among individuals with OUD for all outcomes of interest (i.e. 
SIB, suicidal ideation, suicide attempt). Commonly associated co-occurring psychiatric 
diagnoses reported for patients with SIB, suicidal ideation, and attempt included anxiety, PTSD, 
and borderline personality disorder. Collectively, these findings support greater psychiatric 
comorbidity with SIB and suicide attempt among those with OUD.  
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Likewise, prior to onset of attempted suicide many individuals with OUD reported 
significant life experiences. A study by Darke and Ross (2001) found that 82% of patients with 
OUD reported that a major life event had preceded their most recent suicide attempt. Research 
has found that the most commonly reported life events, prior to a suicide attempt among clients 
with OUD, was the conflict or  dissolution of a primary relationship (Darke & Ross, 2001; Heale 
et al. 2003), bereavement (Darke & Ross, 2001; Heale et al. 2003), and impending incarceration 
(Darke & Ross, 2001). This finding highlights the complexity of the social dynamics; reinforcing 
that maintaining social relationships and a support system is key in attaining positive outcomes.  
Overlap in SIB and suicide methods is important because SIB is associated with 
increased risk of a suicide attempt. Previous research has found that cutting is a common form of 
both SIB and suicide among individuals with OUD. One study found that cutting primary form 
of SIB for 25% of treatment seeking OUD patients (de los Cobos et al., 2007). A second study 
found that 74% of study participants with OUD engaged in cutting as their predominant form of 
SIB (Oyefeso et al., 2008). Additionally, three studies found cutting to be in the top three most 
common means of suicide attempt among individuals with OUD (Conner et al., 2007; Kazour et 
al., 2016; Neale, 2000). Although it is unknown if SIB is systematically assessed in OUD 
treatment, this overlap provides insight for means reduction and a identifies a potential point for 
early intervention. Additionally, while a majority of studies utilized participants who primarily 
used heroin, however, heroin overdose was not a common method of suicide attempt (Vingoe et 
al., 1999). Likewise, although heroin was most frequently reported in overdoses, it was 
significantly more likely to be used in an accidental or unintentional overdose than an intentional 
overdose (Maloney et al., 2007; Neale, 2000). This is unclear whether this is due to lack of 
validated instruments to differentiate intentionality of overdose or if this is a result of assessment 
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bias. However, the most frequently cited methods of suicide attempt were overdose of non-
opioid pills (Conner et al., 2007; Maloney et al., 2007), followed by cutting and hanging (Conner 
et al., 2007). Overall, firearms were the least likely to be used in attempted suicide among 
individuals with OUD, contrary to statistics normally reported on the US population. Although a 
study of veterans suggests firearms are the most common method used in a suicide attempt, they 
were more commonly used among individuals without a SUD diagnosis (Bohnert et al., 2017). 
This same study found that poisoning was the most common method of attempted suicide among 
individuals with a current SUD diagnosis (Bohnert et al., 2017). In 2017, firearms were the most 
common method of death by suicide, accounting for 50.6% of all suicide deaths (Kochanek et 
al., 2017), versus 13.9% for poisoning (Kochanek et al., 2017).  
Overall, the relationship between self-injurious behaviors, suicidal ideation, suicide 
planning, and suicide attempt has been investigated to varying degrees throughout the published 
literature. However, there is still a lack of prospective longitudinal data that provide adequate 
temporal information between onset of OUD and SIB and/or suicide outcomes. Moreover, the 
relationship between SIB, suicidality, and overdose remains under-researched. In general, 
patients with OUD at highest risk of attempted suicide and SIB tended to have more severe 
psychiatric profiles, have increased rates of poly-drug use, experienced significant life stressors 
and childhood maltreatment. These findings provide critical information for treatment 
paradigms, including points for intervention and increased services. In order to address the 
complex nature of overlapping SIB, suicidality, and overdose among individuals with OUD this 




1.2 Specific Aims 
Specific Aim 1: Conduct a systematic literature review of self-harm behaviors among people 
with illicit opioid use or opioid use disorder.  
Specific Aim 2: Assess the feasibility and acceptability of a standardized screen to measure self-
harm and suicide for individuals in OUD treatment.  
Sub-aim 2A: Develop a standardized assessment of self-injury and suicide for patients 
receiving addiction treatment services. 
Sub-aim 2B: Evaluate the acceptability of a standardized screening tool to identify self-injury 
and suicide risk in addiction treatment facilities. 
Hypothesis 1:  For patients, if the time burden is low and understandability is high, we 
anticipate that their willingness to complete the assessment will be high.  
Hypothesis 2: For clinical staff, if screening does not impose increased clinical burden and 
can provided information perceived as useful their willingness to integrate the screening tool into 
clinical practice will be more likely than if perceived burden to clinical staff if high.  
Specific Aim 3: Assessment of clinical profiles for three patient groups: 1) unintentional 
overdose only, 2) suicidal ideation and suicide attempt (SI/SA), and 3) suicidal ideation, suicide 
attempt, and unintentional overdose (SI/SA/OD). In order to determine group differences 
multinomial logistic regression models will be employed to evaluate the relationship between 
groups with age of onset of substance use, age of initiation of SIB, last episode of self-injury, 
ACE domain scores, and past year stressful life experiences for each of the three groups.  
Hypothesis 1: Previous research has related ACEs to earlier age of initiating opioid use, 
recent injection drug use, and lifetime overdose (Stein et al., 2017). Likewise, studies 
have reported that accumulation of ACEs increases the odds of both suicidal ideation and 
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suicide attempt. Based on previous research, it is believed that perceived stressful life 
events will be associated with SI/SA while ACE domain scores will be an overlapping 
factor in both SI/SA (Chen et al., 2009) and the unintentional overdose groups (Stein et 
al., 2017).  
Hypothesis 2: Furthermore, subjects with more recent episodes of SIB will represent the 
group with a more severe behavioral profile (i.e SI/SA/OD) who engage in more high-



















2. Factors Associated with Self-Injurious Behavior, Overdose, and Suicide Among  
    Individuals with Opioid Use Disorder: A Systematic Review 
2.1 Abstract 
Background: Both suicide and opioid use disorder (OUD) represent significant threats to public 
health. In 2018, more than 1.9 million US adults 18 years and older had an OUD; while 1.4 
million adults attempted suicide that same year. The key to understanding this relationship is 
examining behaviors that often precede these potentially fatal acts, such as self-injurious 
behavior (SIB). The overall objective of this systematic review is to better understand the 
relationship between SIB, overdose and/or suicidal behaviors among people with OUD.  
Methods: A systematic literature review was conducted of research studies that examined 
overdose, SIB, suicide, and OUD. The literature search was conducted in accordance with 
PRISMA guidelines for systematic reviews and meta-analysis. 
Results: Forty-seven studies were included that examined the relationship between overdose, 
SIB, and/or suicidal behavior among people with OUD. Of these studies 46 were assessed using 
the NHLBI quality tool, of which 17.4% were rated as poor, 32.6% were rated as fair, and 50.0% 
of studies were rated as good. Seven common themes were identified including: patterns of 
substance use, psychological factors/diagnoses, sociodemographic characteristics, family history, 
traumatic life events, sex, and methods of suicide attempt. 
Conclusions: In general, patients with OUD who are at highest risk of suicide attempt and SIB 
have more severe psychiatric profiles, are female, have increased rates of poly-drug use, and 
experienced significant life stressors and childhood maltreatment. Collectively this information 
has implications for resource needs, treatment, and prevention.  
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2.2 Introduction                                                                                                           
Both suicide and opioid use disorder (OUD) represent significant threats to public health. In 
2018, more than 1.9 million adults 18 years and older in the United States (US) had an OUD. 
That same year, 1.4 million adults ages 18 or older attempted suicide (SAMHSA, 2019). 
However, a key to understanding the relationship between these two conditions is to examine 
key behaviors that precede these potentially fatal behaviors. Approximately 50–60% of people 
who die by suicide have a documented prior history of self-injurious behavior (SIB) (Foster et 
al., 1997) with many instances of SIB occurring shortly before their fatal act (Gairin et al., 2003). 
Yet, limited information is available with regard SIB and future risk for death by suicide, 
specifically, in terms of the prevalence and relationship with lifetime SIB (O’Connor et al., 
2018). To date, four articles have assessed the published literature in a systematic review of the 
relationship between substance use disorders (SUDs) and suicide (Bohnert et al., 2010; Colledge 
et al., 2020; Harris & Barraclough, 1997; Wilcox et al., 2004). To varying degrees, each has 
expanded upon the connection between SUDs and mental health disorders. However, until the 
recent meta-analysis published by Colledge and colleagues (2020), no review has systematically 
investigated precursors of suicide and SUDs or a specific SUD (other than alcohol use disorder) 
and risk factors highly correlated with suicide. Specifically, Colledge colleagues explore the 
relationship between depression, post-traumatic stress and injection drug use (IDU) (2020). 
Findings from their analysis indicate that adding suicide prevention to harm-reduction services 
should be a considered priority based on the strong relationship between self-harm, depression, 
and IDU (Colledge et al., 2020). Intentionality of overdose is often hard to ascertain and is an 
outcome that can blur the lines between SIB and suicide attempts. In order to better understand 
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the relationship between SIB and/or risk of suicide among people with OUD, a systematic 
review of published literature was conducted to gauge the current body of literature. 
Self-injurious behavior (SIB) is defined as the deliberate destruction of body tissue without 
suicidal intent, for purposes not deemed socially acceptable. Included are such behaviors as 
cutting, burning, head banging, picking at wounds, and self-biting (ISSS, 2007). SIB and suicide 
attempts are linked to increased risk of death by suicide (Cooper et al., 2005; Hawton et al., 
2012; O’Connor & Nock, 2014; O’Conner et al., 2016; Turecki & Brent, 2016). A majority of 
research studies conducted on SIB utilize adolescent samples, with far fewer studies focusing on 
adult populations under the assumption that these behaviors decrease in adulthood (Plener et al., 
2016). However, an early study conducted by Briere and Gill (1998) using a stratified, random 
sample of adults estimated the 6-month prevalence of SIB in adults to be 4% in the United States 
(US). Although substantially less attention is paid to co-occurring SIB and SUDs, rates of these 
behaviors are also elevated in this population. Previous research found individuals with SUDs 
have a 10-46% prevalence of SIB compared to 2-4% reported for the general population (Evren 
& Evren, 2005; Harned et al., 2010; Maloney et al., 2010). Episodes of SIB are one of the most 
important risk factors for future suicide (Cavanagh et al.,2003). When specifically looking at 
people with OUD, previous research has found these individuals have a standardized mortality 
ratio approximately 14 times greater than those without OUD (Darke & Ross, 2002; Harris & 
Barraclough, 1997; Tremeau et al., 2008; Wilcox et al., 2004).  
A previous meta-analysis by Harris and Barraclough (1997) broadly examined the 
relationship between 44 mental health diagnoses and their standardized mortality ratio (SMR) for 
suicide. The overall analysis found that 36 of these diagnoses had excess SMRs relative to the 
overall population. Specifically, they found that substance abuse was associated with two-fold 
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higher risk of mortality when compared to other mental health diagnoses (Harris & Barraclough, 
1997). In 2004, Wilcox and colleagues expanded upon the previous work of Harris and 
Barraclough in estimating SMRs and SMRs stratified by sex. Their updated review also included 
evaluation of subcategories of SUDs focusing on alcohol use disorder (AUD), OUD, intravenous 
drug use (IDU), mixed drug use, and heavy drinking (Wilcox et al., 2004). However, this review 
did not account for behavioral precursors to suicide or behaviors highly correlated with suicide. 
Wilcox and colleagues (2004) make a point in their review to address the dearth of literature on 
AUD and suicide, distinguishing that only a somewhat moderate amount of attention is paid to 
OUD and suicide. They concluded that limited prospective data on the use of other specific 
substances of abuse and associations with suicidal behavior manifests in published research. A 
2010 review assessed the overlap and risk factors of unintentional overdose and suicide among 
substance users (Bohnert et al., 2010) and identified substance use as a risk factor for suicide, 
suicide attempts, and both fatal and non-fatal overdoses.  
Previous literature has found that people with OUD have a nearly fifteen times greater risk of 
all-cause mortality than demographically matched controls, with overdose being the leading 
cause of death (Degenhardt, et al., 2010). In the US, 70,237 people died from overdose in 2017 
(Hedegaard et al., 2018). Of these deaths, opioids were responsible for 47,600 (67.8%) 
(Hedegaard et al., 2018). However, for every overdose resulting in death, there are many more 
nonfatal overdoses. Likewise, having one overdose substantially increases the risk of repeat 
overdose (Larochelle et al., 2016; Hasegawa et al., 2014) and markedly elevates short-term risks 
of mortality (Kelty and Hulse, 2017; Stoove et al., 2009). One study, in a cohort of Austrian 
opioid users, found that following an overdose, people with OUD were nearly 50 times more 
likely to die than matched community controls, with most of the deaths involving an opioid 
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(Risser et al., 2001). However, disentangling the complex relationship between intentional and 
unintentional overdoses, even among those overdoses that are nonfatal, remains difficult. In this 
context, repeated overdoses could straddle the line of SIB and suicide attempt(s). 
The overall objective of this systematic review is to improve our understanding of 
relationship between self-injurious behavior (SIB), overdose and/or suicidal behaviors (i.e. 
suicidal ideation, suicide planning, and suicide attempt) among people with OUD. To achieve 
this end, the systematic review has two aims: (1) to examine the association between a history of 
SIB, overdose and/or suicidal behavior in people with OUD and (2) to examine the potential 
overlapping factors and clinical implications of these behaviors among people with OUD. Thus, 
the innovation of this review is the aim to address behaviors associated with increased risk for 
suicidality and OUD to more effectively potential risks and treatment implications associated in 
populations with multiple morbidities. Furthermore, this review addresses the overlap of 
overdose with SIB and suicidality, which hitherto has not been explored. Finally, a thematic 
analysis of research evidence, limitations, and future directions will be discussed.  
2.3 Methods 
Search Strategy 
The literature search followed PRISMA guidelines for systematic reviews and meta-analysis 
(Moher et al., 2009). Articles were retrieved through a systematic search of electronic peer-
review literature across three databases:  the U.S. National Library of Medicine’s PubMed 
electronic database, the American Psychological Association’s PsycINFO electronic database, 
and the Institute for Scientific Information’s Web of Science electronic database. All databases 
were searched for articles published between January 1, 1998 and August 31, 2018. A 20-year 
timeframe was selected to overlap intentionally with the review published by Bohnert and 
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colleagues (2010), and to capture new, relevant studies on this topic and to expand to include 
literature addressing SIB.  
Each database had a slightly different search structure. To accommodate varying search 
parameters, terms were coupled with relevant MeSH/thesaurus terms and truncated, with spelling 
variations as appropriate. A combination of the following terms “self-harm,” “self- injury,” 
“deliberate self-harm,” “self-directed violence,” “self-injurious behavior,” “non-suicidal self-
harm,” “suicide,” “opioid abuse,” “opioid misuse,” “heroin abuse,” “narcotics abuse,” “opiate 
abuse,” “opiate misuse,” “opiate use disorder,” and “opioid use disorder” were used within the 
search parameters for article retrieval.  
Studies were limited to research articles published in peer-reviewed journals available in 
English. The search results were imported into a bibliographic software program (EndNote X9), 
and duplicated articles were removed. Articles were excluded if they: (1) failed to provide new 
data (e.g., review articles), (2) data were limited to case reports or only descriptive in nature, (3) 
their sample was limited to children (i.e., the sample age cutoff was <18 years), (4) their sample 
excluded persons who used opioids or had a sub-group of participants with opioid use, abuse, or 
OUD (i.e., clustered substances of abuse together), (5) they did not examine SIB and/or suicide 
and opioid use/OUD, (6) the study examined both SIB and/or suicide and opioid use/OUD but 
did not test for an association between these outcomes (i.e., did not provide data on outcomes 
relative to one another beyond prevalence), and/or (7) the study was conducted using toxicology 
or post-mortem data only. Titles and abstracts were independently screened, and then full texts 
were reviewed to identify eligible studies. Reference lists from eligible research articles were 
searched for further studies that might be included in the final review. Any disagreements in 
article inclusion were resolved by discussion or between the co-authors. 
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Quality Assessment 
The quality of studies was examined using the National Heart, Lung, and Blood Institute 
(NHLBI) quality assessment tool (2014). This tool was chosen because it evaluates quality based 
on study design. The tool employs one check list tailored for observational cohort and cross-
sectional studies and another checklist for case-control studies. Both checklists were developed 
to address internal validity (i.e., risk of bias) in an equivalent manner. Each checklist item was 
rated as “yes,” “no,” “not applicable (NA),” “cannot determine (CD),” or “not reported (NR).”  
These items then inform an overall quality rating for each study as “good,” “fair,” or “poor.” 
2.4 Results 
The PubMed search resulted in 672 articles, the PsycINFO search identified 970 articles, 
and the Web of Science search yielded 972 articles. After deletion of duplicate articles, a total of 
1,631 unique articles remained. Following an initial article inspection (i.e. title and keywords), 
143 abstracts were reviewed and a total of 47 articles remained that were relevant to this 
systematic review (Figure 2.1). 
Twenty-six of the 47 studies examined more than one outcome. Ten studies examined 
overdose and suicide attempt (Best et al., 2000; Bradvik et al., 2007; Conner et al., 2007; Darke 
& Ross, 2001; Heale et al., 2003; Neale, 2000; Ross et al., 2005; Rossow & Lauritzen, 1999; 
Ravndal & Vaglum, 1999; Vingoe et al., 1999),  one additional study examined overdose with 
SIB and suicide attempts (de los Cabos et al., 2007), and another included all drug poisonings 
(Olsson et al., 2016). Five studies reported on suicidal ideation and suicide attempt (Cheek et al., 
2016; Kazour et al., 2016; Kuramoto et al., 2012; Maloney et al., 2009; Wines et al., 2004). Four 
studies assessed suicide planning, in addition to suicidal ideation and suicide attempt 
(Ashrafioun et al., 2017; Darke et al., 2015; Havens et al., 2004; Marchand et al., 2017). Five 
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studies examined SIB and suicide attempt (Baykara & Alban, 2018; Darke et al., 2010; Darke et 
al., 2012; Harned et al., 2006; Maloney et al., 2010). One study examined suicide attempt, 
overall suicide risk, fatal accidental intoxication, and injury/intoxication of undetermined intent 
(Olsson et al., 2016) (Table 2.1).  
Quality of Studies 
Forty-six studies in the present review used quantitative methods that could be evaluated 
using the NHLBI quality assessment tool. One study employed a mixed methods design and 
primarily reported qualitative data (Neale, 2000). Hence it was not assessed for quality. Of the 
studies assessed using the NHLBI quality tool, 17.4% had an overall rating of poor, 32.6% were 
rated as fair, and 50.0% good. Forty-two of the studies relied on self-report measures, 66.7% of 
which did not use validated measure for suicide, overdose, or SIB outcomes. Recall bias was the 
predominant research limitation across all studies included in the review. Seventy-two percent of 
studies use statistical modeling to address potential confounding by controlling for known 
covariates associated with the outcome of interest. However, only 21.7% (n=10) of the studies 
provided calculations for sample or effect sizes (Table 2.2).  
Themes 
Patterns of Substance Use 
Twenty-six studies reported on patterns of substance abuse associated with SIB and suicidal 
behaviors. Four studies analyzed the relationship between SIB and OUD. Of these studies, three 
found that SIB was associated with increased likelihood of having OUD (Darke et al., 2010, 
Lavania et al., 2012, & Maloney et al., 2010). Two of these studies also found an increased rate 
of AUD and OUD (Darke et al., 2010 and Maloney et al., 2010). One study found that patients 
with a dually diagnosed AUD and OUD were more likely to report SIB. However, they were less 
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likely to report suicide attempts than participants with other SUDs (Darke et al., 2010). Five 
studies assessed the relationship between suicidal ideation and OUD. Three studies found that 
OUD was associated with a statistically increased likelihood of suicidal ideation (Ashrafioun et 
al., 2017, Kuramoto et al., 2012, & Jin et al., 2013), specifically among samples with individuals 
who predominantly used heroin.  
Eighteen examined suicide attempts or risk and OUD. The most common overlapping 
risk factor between OUD and suicide attempt(s)/risk of suicide was poly-drug use (Darke & 
Ross, 2001; Darke et al., 2004; Darke et al., 2015; Hakansson et al., 2010; Harned et al., 2006; 
Havens et al., 2004; Rossow & Lauritzen, 1999). Additionally, four studies found the likelihood 
of recent heroin overdose (Darke et al., 2004), history of overdose (Hankansson et al., 2010), and 
history of a suicide attempt increased with the number of previously reported heroin overdoses 
(Bradvik et al., 2007; Rossow & Lauritzen, 1999).  
Psychological Factors/Diagnoses 
Twenty-four studies reported specific psychological symptom and /or psychiatric 
diagnoses associated with suicidal behaviors, SIB, and OUD. Fifty-four percent of studies 
reported an association with suicidal behaviors and/or SIB and major depressive disorder or 
depressive episodes. Two studies found that study participants who met the criteria for both 
OUD and SIB also were more likely to have met the criteria for a depressive episode (Maloney 
et al., 2010) and had significantly higher scores on the Beck Depression Scale than patients 
without SIB (Baykara & Alban, 2018). In addition, one study found that treatment with 
antidepressant medication was a significant predator of suicide attempt among those with OUD 
(Roy, 2010). Two studies found that participants with OUD, suicide attempts, and SIB were 
more likely to have been diagnosed with borderline personality disorder (Darke et al., 2004; 
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Maloney et al., 2010). Another frequently reported psychiatric diagnosis was posttraumatic stress 
disorder (PTSD). Two studies found that a recent suicide attempt among participants with OUD 
was associated with a diagnosis of PTSD (Darke et al., 2004; Darke et al., 2015). One of these 
studies found PTSD to be significantly associated with SIB among those with OUD (Darke et al., 
2004). Three additional studies reported overall increased reporting of overall history of mental 
health problems: one specifically with regards to intentional overdose (Neale, 2000), another 
reported higher odds of suicidal ideation (Marchand et al., 2017), and a third found that patients 
with a history of both a suicide attempt and overdose had increased psychiatric problems—
specifically anxiety, depression, and suicidal ideation (Rossow & Lauritzen, 1999).  
Family History 
Six studies investigated the association between family history of suicidal behaviors and 
suicidal behaviors, SIB, and OUD. Two studies found that people with OUD were more likely to 
report a history of suicide attempts among family members (Dragisic et al., 2015; & Roy, 2002). 
One more found that family history of suicidal behavior predicted a suicide attempt in people 
with OUD (Roy, 2010). Additionally, another study found that maternal alcohol use or 
psychiatric problems and paternal alcohol problems were significantly associated with a suicide 
attempt in patients with OUD (Hakansson et al., 2010).  
Role of Gender 
Fifteen studies investigated the role of gender and suicidal behaviors or SIB and OUD. 
Three studies found that females with OUD were significantly more likely to report a history of 
SIB than males (Darke et al., 2010; Darke et al., 2012; Maloney et al., 2010). Seven reported an 
association between gender and a suicide attempt among participants with OUD. Similar to the 
studies that examined this relationship to SIB, females with OUD were significantly more likely 
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to have a history of a suicide attempt(s) than males (Bohnert et al., 2017; Hakansson et al., 2010; 
Kazour et al., 2016). Females with OUD who attempted suicide also were more likely to be 
younger than those with no such history (Dark et al., 2012; Roy 2012), attempt suicide more 
frequently than males (Darke et al., 2001; Darke et al., 2015; Maloney et al., 2007; Tremeau et 
al., 2005), and use less lethal methods (Icick et al., 2017). Two studies found that females were 
more likely than males to have attempted suicide prior to the onset of heroin use (Darke & Ross, 
2001; Maloney et al., 2007), with one finding that males were more likely than females to be 
using heroin at the time of their most recent suicide attempt (Darke & Ross, 2001). 
Sociodemographic Factors 
Ten studies examined sociodemographic characteristics associated with the relationship 
between suicidal behaviors, SIB, and OUD. Four studies investigated age at time of suicide 
attempt and/or SIB. Overall, younger OUD patients were more likely than older counterparts to 
have attempted suicide (Baykara & Alban, 2018; Roy 2010). Consistent with previous research, 
OUB patients engaged in SIB at a significantly younger than their age of a first suicide attempt 
(Darke et al., 2012), primarily beginning in adolescence (Maloney et al., 2010). Conversely, 
another study reported that risk of suicide attempt was associated with older age among patients 
with OUD (Hakansson et al., 2010). Two studies found that suicidal ideation was significantly 
more common among OUD patients who lived alone (Darke et al., 2015; Maremmani et al., 
2007). Similarly, overdoses were reported more frequently among people who were homeless, 
had only drug-using friends, or no friends at all (Rossow & Lauritzen,1999). Marital status, 
specifically being unmarried or divorced was also significantly associated with an increased risk 
of suicide attempt/suicidal ideation and OUD (Darke et al., 2015; Dragisic et al., 2015; Jin et al., 
2013). Additionally, two of the studies found that participants with OUD, who more frequently 
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reported suicidal ideation and suicide attempts, were significantly more likely than those who 
reported less frequency to be unemployed (Darke et al., 2015; Maremanni et al., 2007).                          
Childhood and Adulthood Life Events 
Eleven studies evaluated the contribution of both childhood and adult life events and their 
association with suicidal behaviors and SIB among patients with OUD. Participants with OUD 
who experienced childhood maltreatment/trauma (i.e. emotional abuse, physical abuse, sexual 
abuse, emotional neglect, and physical neglect) were more likely to report a history of suicide 
attempt(s) (Kalyoncu et al., 2007; Maloney et al., 2007; Maloney et al., 2010; Roy 2002). One 
study reported that for each unit increase in the childhood emotional neglect score, the adjusted 
odds of suicidal ideation increased by nine percent (Marchand et al., 2017). Participants with 
OUD and a self-reported history of SIB were also more likely to report every subtype of 
childhood maltreatment, particularly sexual abuse and neglect (Maloney et al., 2007). Individuals 
who reported experiencing a violent physical assault, before age sixteen were significantly more 
likely to self-report a history of SIB and a suicide attempt (Darke et al., 2012). Furthermore, 
participants with OUD and prior sexual assault were more likely to report severe suicidal 
ideation (Gilmore et al., 2008). History of emotional, physical, and sexual abuse was also 
positively and independently associated with a history of attempted suicide (Hakansson et al., 
2010). In adulthood, the number of stressful or traumatic life events was significantly associated 
with that outcome (Chen et al., 2009; Marchand et al., 2017). One study of young IDUs found 
that the odds of a suicide attempt increased by 22% with each violent exposure reported (Havens 
et al., 2004). Similarly, the number of stressful life events experienced by a person was 
positively associated with self-reported SIB (Lavania et al., 2012). 
Triggers for Behavior and Methods of Suicide Attempt 
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Eight studies reported on behaviors associated with methods of suicide attempts and/or 
SIB or triggers for engaging in those behaviors. The most commonly reported method of 
attempted suicide was overdose using non-opioid pills (Conner et al., 2007; Maloney et al., 2007; 
Vingoe et al., 1999). In the two studies that did report opioids as the primary method of suicide 
attempt, the sample was predominately heroin users who attempted suicide via heroin overdose 
(Kazour et al., 2016; Neale, 2000). The two most commonly reported triggers of attempted 
suicide were a conflict or dissolution in the primary relationship and bereavement (Darke & 
Ross, 2001; Heale et al., 2003). 
2.5 Discussion 
Main Findings   
This systematic review included 47 studies that examined the relationship between 
overdose, SIB, suicidal ideation, and suicide attempts among patients with OUD. To date, four 
review articles have reviewed the literature examining the association between substance use 
disorders (SUDs) and suicide (Bohnert et al., 2010; Colledge et al., 2019; Harris & Barraclough, 
1997; Wilcox et al., 2004). To varying degrees, each has expanded upon this connection; 
however, until Colledge and colleagues (2019), no review has systematically investigated 
precursors of suicide and SUDs or at a specific SUD (other than alcohol use disorder) and risk 
factors highly correlated with suicide. Understanding these precursors of suicidal behavior and 
the overlapping risk factors between OUD and SIB are key in examining risks for potentially 
fatal behaviors. 
In 2018, individuals with any mental health diagnosis are substantially more likely to 
misuse opioids in the past year than individuals without any comorbid mental health diagnosis 
(SAMSHA, 2019). According to the 2018 National Survey of Drug Use and Health, adults with a 
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diagnosis of any mental illness were 9.2% more likely to have past year opioid misuse and adults 
with a serious mental illness were 14.6% more likely to have past year opioid misuse; this is 
compared to the 2.6% of the US population over 18 years old with past year opioid misuse and 
no co-occurring mental health diagnosis (SAMSHA, 2019). Consistent with these findings, fifty-
one percent of the studies in this review reported associations between psychiatric diagnoses, 
SIB, and suicidality among individuals with OUD. Studies consistently reported that depression 
scores are consistently higher, or history of major depressive episode is present among 
individuals with OUD for all outcomes of interest (i.e. SIB, suicidal ideation, suicide attempt). 
Commonly associated co-occurring psychiatric diagnoses reported for patients with SIB, suicidal 
ideation, and attempt included anxiety, PTSD, and borderline personality disorder. Collectively 
these findings support greater psychiatric comorbidity with SIB and suicide attempt among those 
with OUD.  
Overall, females were more likely to report a history of SIB, suicidal ideation, and 
suicide attempt, which is similar to that found in the general population (Bohnert et al., 2017; 
Hakansson et al., 2010; Kazour et al., 2016; Olfson et al., 2017). Females were also more likely 
to make multiple attempts (Darke et al., 2012; Darke et al., 2015; Tremeau et al., 2005). Females 
were also more likely to report recent episodes of SIB (past 12-months) despite older age 
compared to males (Darke et al.,2012), though age of onset of SIB consistently occurred in 
adolescents and before the first suicide attempt was made for both males and females (Darke et 
al., 2012; Maloney et al., 2010). One study reported that females with OUD were 2-3x more 
likely to die by suicide than males (Bohnert et al., 2017). This is contrary to statistics reported 
among the general population in the US where men are 3.54 times more likely to die by suicide 
than women (Kochanek et al., 2017). Specifically, with regards to heroin use, it was noted the 
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females were more likely to attempt suicide prior to the onset of heroin use compared to males 
(Maloney et al., 2007), with one study reporting that females were 18 times more likely to 
attempt suicide before initiation of heroin use compared to males (Darke & Ross, 2001). These 
studies suggest that females with OUD are not only at higher risk of suicide attempt, but at 
higher risk for making multiple attempts when compared to males irrespective of transition to 
heroin use. This could in part be due to co-occurring risks for other psychiatric diagnoses; 
however, given higher reporting rates of SIB among females suicide risk remains a significantly 
greater threat among females.  
Nationally representative samples have found that adults in the US reporting recent 
suicide attempts are more likely to be female, white, unemployed, and have a family history of 
suicide attempt irrespective of any other comorbid health diagnoses (Olfson et al., 2017). 
Additionally, being widowed, divorced, or unmarried was also significantly associated with 
suicide attempt independent of mental health or SUD diagnosis (Olfson et al., 2017). Findings 
from several studies reporting on demographic characteristics in combination with suicidality 
among individuals with OUD are consistent with those reported in the general population. 
Specifically, being unmarried (Dragisic et al., 2015; Jin et al., 2013; Maremmani et al., 2007), 
unemployed (Darke et al., 2015; Jin et al., 2013), living alone (Darke et al., 2015; Maremmani et 
al., 2007) and homeless (Rossow & Lauritzen, 1999) were all significantly correlated with 
increased history of suicidal ideation. Likewise, one study included in this review also reported 
that irrespective of diagnosis of OUD patients with history of suicide attempt were more likely to 
have a family member with a history of suicide attempt (Maloney et al., 2007) which coincides 
with reports from research done in general samples. Although these factors were not consistently 
examined across studies included in the review, several consistencies are present in demographic 
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characteristics associated with suicidality independent of OUD diagnosis. This overlap in 
employment status, marital status, and family history can potentially help identify global 
characteristics of suicidality that remain constant irrespective of diagnosis of OUD. 
An important finding from this review is the role of treatment. Although few studies 
measured the impact of treatment with respect to the outcomes of interest (i.e. SIB, suicidal 
ideation, and/or suicide attempt); several studies did provide some key points. Patients with 
OUD in treatment settings who reported suicide attempts generally tended to be in overall poorer 
health or have chronic medical conditions (Darke et al., 2015; Hakansson et al., 2010; Roy, 
2010). Likewise, previous number of times detoxed was positively associated with number of 
suicide attempts (Kazour et al., 2016). Similarly, patients with deliberate overdoses were more 
likely to be in treatment at the time of overdose (Best et al., 2000). 
Prior to onset of suicide attempt many individuals with OUD reported significant life 
experiences. A study by Darke and Ross (2001) found that 82% of patients with OUD reported 
that a major life event had preceded their most recent suicide attempt. Research has found that 
the most commonly reported life events prior to suicide attempt among clients with OUD was 
the breakdown of a primary are conflict or  dissolution of a primary relationship (Darke & Ross, 
2001; Heale et al. 2003), bereavement (Darke & Ross, 2001; Heale et al. 2003), and impending 
incarceration (Darke & Ross, 2001). This highlights the complexity of the social dynamics; 
particularly, as mentioned earlier, that living alone, and poor social functioning are also 
associated with increased risk for both suicidal ideation and suicide attempt. Maintaining social 
relationships and having support is key in attaining positive outcomes.  
While a majority of studies utilized participants who primarily used heroin, interestingly, 
heroin overdose was not a common method of suicide attempt (Vingoe et al., 1999). Likewise, 
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even though heroin was most frequently reported in overdoses, it was significantly more likely to 
be used in an accidental overdose than a deliberate overdose (Maloney et al., 2007; Neale, 2000). 
This is unclear whether this is due to lack of validated instruments to differentiate intentionality 
of overdose or if this is a result of assessment bias. However, the most frequently cited methods 
of suicide attempt were overdose of non-opioid pills (Conner et al., 2007; Maloney et al., 2007), 
followed by cutting and hanging (Conner et al., 2007). Overall, guns were the least likely to be 
used to attempt suicide among individuals with OUD contrary to statistics normally reported 
among suicide attempts in US population. Although a research done among veterans suggests 
that firearms are the most common method used in suicide attempt, firearms were more 
commonly used among individuals without any SUD diagnosis (Bohnert et al., 2017). This same 
study found that the most common methodology for suicide attempt among individuals with any 
current SUD diagnosis was poisoning (Bohnert et al., 2017). In 2017, firearms were the most 
common method of death by suicide accounting for 50.6% of all suicide deaths (Kochanek et al., 
2017); whereas poisoning accounted for 13.9% of suicide deaths in the US (Kochanek et al., 
2017).  
Overlap in SIB and suicide methodology are of importance because SIB is associated 
with increased risk of suicide attempt. Previous research has found that cutting is a common 
form of both SIB and suicide among individuals with OUD. One study found that 25% of 
treatment seeking OUD patients primary form of SIB was cutting (de los Cobos et al., 2007). A 
second study found that 74% of study participants with OUD engaged in cutting as their 
predominant form of SIB (Oyefeso et al., 2008). Additionally, three studies found cutting to be 
in the top three most common forms of suicide attempt among individuals with OUD (Conner et 
al., 2007; Kazour et al., 2016; Neale, 2000). Although it is unknown if SIB is systematically 
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assessed in OUD treatment, this overlap provides insight for means reduction and a potential 
point for early intervention. 
Implications 
A total of two studies reported an overall increased risk of suicide specifically associated 
with OUD. One of these studies found that inpatients with heroin use had a 16-fold increase in 
standardized mortality ratio due to suicide compared to the general population (Pan et al., 2014). 
A second, reported 1.76 odds of death by nonviolent suicide among individuals with OUD 
compared to those without OUD (Ilgent et al., 2009). Two indicators of substance use severity 
were found to be associated with suicide attempt in this review: age of onset of opioid use and 
IDU. Several studies reported that an earlier onset of substance use was associated with 
increased risk of suicide attempt among people with OUD (Dragisic et al., 2015; Havens et al., 
2004; Icick et al., 2017; & Kazour et al., 2016). Likewise, IDUs with OUD also had an increased 
risk for suicide attempt (Dragisic et al., 2015; Hakansson et al., 2010; Masferrer et al., 2016). 
Both of these factors overlap with risk of suicide attempt and risk for potential overdose marking 
increased severity of substance use. Furthermore, as summarized by previous studies those who 
maintain relationships with only friends in the drug use community are further at risk of suicidal 
behaviors. The connection between these factors indicates that poor social functioning, 
psychiatric decline, and substance use not only correlate to suicidality but represent key factors 
for intervention.  
Limitations 
Twenty-six studies were cross section, thus temporal conclusions could not be drawn 
linking onset of OUD with SIB, suicidal ideation, and/or suicide attempt. Five studies included 
longitudinal data limiting the ability to identify true causal relationships between OUD and SIB 
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and/or suicidal behaviors due to lack of temporal information. Furthermore, a majority of this 
research was conducted among inpatient or outpatient treatment samples which limits 
generalizability. It is also unknown whether treatment seeking individuals have more functional 
impairments or experience more symptom severity than non-treatment seeking individuals. 
Likewise, limited studies are conducted in low-income, rural areas which may have different 
patterns of substance use and barriers to treatment further contributing to the variability in 
estimation of SIB and suicide among people with OUD. Only one study in this review examined 
overdose and SIB indicating a need for further investigation of this relationship in future 
research, especially given the strong connection between SIB and future risk for suicide attempt.  
2.6 Conclusions 
Overall, the relationship between self-injurious behaviors, suicidal ideation, suicide 
planning, and suicide attempt has been investigated to varying degrees throughout the published 
literature. However, there is still lack of prospective longitudinal data providing adequate 
temporal information between onset of OUD and SIB and/or suicide outcomes. Furthermore, the 
relationship between SIB, suicidality, and overdose still remains under researched. In general, 
patients with OUD who are at highest risk of suicide attempt and SIB tend to have more severe 
psychiatric profiles, increased rates of poly-drug use, tend to be female, experience significant 
life stressors, and childhood maltreatment. These findings provide crucial points for treatment 
paradigms including points for intervention and increased services to address the complex nature 
overlapping SIB, suicidality, and OUD. 
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planning, SAs (past 12-
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• Adjusted models found that 
prescription opioid misuse was 
significantly associated with SI 
for each frequency category.  
• Individuals who reported an 
average of weekly or more use 
had a significant association 
with suicidal planning and 
attempts. 
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OUD. 
• DSM-V  Opioids Self-Injurious Behavior 
(SIB), SAs (4-6 weeks 
after last use of 
substance; lifetime 
history) 
• Patients with history of OUD & 
SIB had higher subscale scores 
for passive aggression, 
somatization, and immature 
factor.            
• Beck depression and Beck 
anxiety inventory scores were 
higher for patients with both 
OUD and history of SA. 
• Logistic regression analysis 
found that passive aggression 
subscale scores and younger 
age were related to SIB. 
• History of SA was associated 
with younger age, suppression, 
dissociation, somatization, 
higher Beck anxiety inventory, 
low idealization, projection, 
devaluation, splitting, and 
rationalization scores. 
  










Methadone Accidental OD; 
deliberate OD (lifetime) 
• Patients with a deliberate OD 
were more likely to currently be 
taking diazepam, have higher 
depression scores, hopelessness 
scores, more lifetime ODs, & 
OD more recently.  
• The deliberate OD group was 
more likely to be in treatment at 
the time of OD and more 
frequently reported SI in the 
past-month than individuals 

















Key findings/ Summary 








(VHA) users from 
the 2005 fiscal 
year and alive at 
the beginning of 
the 2006 fiscal 
year. 
• National Death 
Index (NDI) & 
ICD-10 (suicide 
mortality)  
• VHA National 
Patient Care 
Database (NPCD) 
and ICD-9 CM 
(SUDs) 








c use disorder 
Suicide Mortality (2006-
2011) 
• 9,087 individuals died by 
suicide (34.7 per 100,00). 
• For men, OUD was the third 
largest risk for suicide                                                                                             
• For women, OUD was the 
second largest risk for suicide  
• Adjusting for mental health 
factors, the only substance 
specific diagnoses to remain 
statistically significant were 
alcohol and OUD for women; 
for men, any SUD, and all 
specific SUDs, remained 
significant risk factors for 
suicide.                                                                          
• Post-hoc analyses found a 2-3x 
greater suicide rate for women 
than men; especially with 
respect to alcohol use disorder, 
cocaine use disorder, OUD, or a 
general SUD diagnosis. 






















SA (lifetme prevalence) • Heroin users were 3.5 times 
more likely to attempt suicide 
than non-users. 
• Current heroin users had an OR 
of 6.1 associated with first-time 
SA  







recruited from the 
needle exchange 
program and the 
Addiction Cent 







unintentional OD, SAs 
• Likelihood of reporting a SA 
increased with the number of 
heroin ODs.  
• Of the 51 persons where heroin 
was not used as a means of SA, 
18 (29%) made multiple 
attempts.  
• When accounting for depressed 
mood and other substances of 
use (alcohol, benzodiazepines, 
cannabis, and central 
stimulants) neither showed a 


















Key findings/ Summary 




10,203 (NR) Adults 18 yrs + 
with lifetime 
history of major 
depression and 
IDU. 
• 2008- 2013 
National Survey on 
Drug Use and 




Substance use (past 12-
months); SI, suicide 
plan(s), SA(s) (2008-
2013; 6 years) 
• IDUs are more likely to have 
increased depressive symptoms, 
SI, plan, and attempt(s).                                                                                        
• Compared non-heroin IDUs, 
those who inject heroin are less 
likely to attempt suicide (OR: 
0.92); however, they are more 
likely to have SI and develop a 








488 (488) Heroin-dependent 
patients recruited 




• Clinical Interview 
("Have you 
attempted suicide 
in the preceding 
one-month? Have 
you attempted 
suicide in your 
lifetime?") 
Heroin, alcohol SA(s) (previous month 
and lifetime) 
• 10.9% of patients had a recent 
SA (past 30 days) and 17.8% 
reported a lifetime SA.                                                                        
• Severity of heroin dependence, 
depression score, levels of 
family support, and number of 
stressful life events, were 
associated with recent SA(s).                        
• Multivariable analyses found 
that severity of heroin 
dependence and needle sharing 
were significantly associated 
with recent SA. 
  
Conner et al. 
(2007)/USA 
Cohort Study  131 (131) Patients from a 
methadone 
program at an 
urban university 




history of OUD 
SA(s) (lifetime and past 
year), unintentional OD 
(lifetime and past year) 
• 37.4% (n=49) of patients 
reported lifetime history of 
SA(s).  
• Of those with a lifetime history 
of SA, 33 (67.4%) had 2+ 
attempts and 7 (14.3%) made 
an attempt in the last year.  
• Most common methods of SA 
were intentional OD (29, 
59.2%), cutting (9, 18.4%), and 
hanging (5, 10.2%).  
• Multivariable analysis found 
that higher belonging score (i.e. 
greater perceived belonging) 
was associated with decreased 



















Key findings/ Summary 











Non-fatal heroin OD, 
SA(s) (lifetime) 
• 40% of participants reported at 
least one SA in their lifetime. 
• Males were significantly more 
likely to be using heroin at the 
time of their most recent SA 
compared to females. 
• 8% of participants were 
receiving psychiatric or 
psychological treatment at the 
time of their most recent SA. 
• 31% of participants had a 
history of both an OD 
(intentional or unintentional) 
and SA(s).  
• Multiple logistic regression 
analysis found that being 
female, parental absence during 
childhood, earlier age of first 
intoxication, and higher levels 
of polydrug use were associated 
with history of SA. 
  




1,230 (1,230) Current heroin 








total number of 
drug classes used 
Lifetime and recent 
attempted suicide   
• 34% of patients had a history of 
SA; females are significantly 
more likely than males to report 
an attempt (44% vs 28%). 
• Recurrent SI was reported by 
23% of patients and 15% 
reported having a current plan. 
• Residential rehabilitation 
patients had a significantly 
higher level of recurrent SI 
compared to other groups. 
• Recent SA was associated with 
lifetime and recent polydrug 
use, recent heroin OD, and 
benzodiazepine use.  
• Recent history of SA was also 
associated with current major 
depression, current SI, 
diagnosis of borderline 
personality disorder, and 
diagnosis of PTSD.  
  



























SA(s), SIB, (lifetime, 
past 12-months) 
• One third of the sample 
reported a lifetime history of 
SIB, 20% had engaged in SIB 
on more than one occasion, and 
10% had SIB in the past 12-
months.  
• Individuals with alcohol and 
opioid use were significantly 
more likely to have a history of 
SIB.  
• Females, PTSD diagnosis, 
younger age of first 
intoxication, and history of SA 
were significantly associated 
with SIB. 
• About 33% of the sample 
reported a history of SA, 17% 
reported multiple SAs, and 15% 
made an attempt in the past 12-
months.  
• 23% of opioid users reported a 
history of SA.  
  














SA(s), SIB, (lifetime, 
past 12-months) 
• Females were more likely than 
males to have engaged in SIB 
in the preceding year, attempted 
suicide, to have multiple 
attempts, have an attempt in the 
12-months, and be younger at 
their first SA.  
• 43% of patients had either 
engaged in SIB and/or 
attempted suicide, 18% 
reported both.  
•  Individuals who experienced 
physical assault before age 16 
were significantly more likely 
to have engaged in SIB and 
have a history of SA compared 
to those who experienced an 
assault after age sixteen.  
• There were no differences in 
weekly psychostimulant users, 
weekly heroin users, or 
combination users in either 
lifetime or 12-month histories 
















Key findings/ Summary 
Darke et al. 
(2015)/Australia 




















months), current SI, 
suicidal plan(s) 
• 34.7% of participants used 
heroin in the 12-months prior to 
follow-up, 24.8% used in the 
month prior, and 9.7% reported 
daily heroin use.  
• 42.2% of ATOS participants 
reported ever having made a 
SA and 18.6% reported making 
multiple attempts at 11-year 
follow-up. 
• Participants that reported a 
recent SA (12 months prior to 
follow-up), having a current 
plan, and/or SI were more 
likely to live alone, be 
unemployed, meet criteria for 
Major Depression and PTSD, 
be in poorer health, and report 
more extensive polydrug use.  
• Diagnosis of Major Depression 
increased the odds of SA by 
1.68 times, each extra drug 















• Clinical evaluation 
conducted by 
psychiatrist  
Heroin SIBs and ODs (during 
course of patients 
reported heroin 
dependence); history of 
bulimia, SA(s) (lifetime) 
• 87.8% of the heroin-dependent 
patients interviewed had a 
history of SIB.  
• Most common SIB: hitting 
extremities (77.4%), picking 
scabs (52.4%), head-butting 
(43.3%), cutting (25%), biting 
(20.7%), carving signs (15.2%), 
scratching (14.6%), burns 
(14%) and pulling out hair 
(9.1%). 
• 25.6% had a history of SA(s), 






















Key findings/ Summary 





200 (200) Individuals 
recovering from 
OUD with and 
without history of 
SA. 
• ICD-10  Opioids SA(s) (lifetime) • Individuals with OUD who 
attempted suicide were more 
likely to be unmarried or 
divorced compared to those 
with OUD who have not 
attempted suicide.  
• Clients with history of SA more 
commonly had psychotic 
disorders, drug addiction, and 
family history of SAs. 
• Persons with OUD and 
attempted suicide also have a 
significantly longer history of 
addiction duration (i.e. 





70 (70) Hospitalized 
patients for SUD.  
• DSM-V 
• California Suicide 
Risk Assessment 
Questionnaire 
Opioids Suicide Risk • Cases were patients with OUD; 
controls were peers without 
OUD 
• Suicide risk wasn’t statistically 
significant between the case 
and control group. 
• Individuals with OUD had a 
significantly higher depression 
scores than controls  




60 (24) Patients who 
received sexual 
assault treatment 
in the ED. 
  
• Self-report 
• Patient Health 
Questionnaire-9 
(SI)   
Opioids SI (past 2 weeks) • Linear regression analysis 
found a significant association 
between prescription opioid use 
and SI. 
• Those with a prior sexual 
assault and OUD reported more 
severe SI  








2001 and August 
2006.  











SA(s) (lifetime) • 21% (n=1,453) of persons 
reported a SA.  
• Logistic regression found: older 
age, female gender, history of 
binge drinking, IDU, delirium 
tremens, OD, chronic medical 
problems, maternal alcohol or 
psychiatric problems, paternal 
alcohol problems, history of 
emotional, physical, and sexual 
abuse, history of depression, 
anxiety, hallucinations, eating 
disorders, and difficulty 
controlling violent behavior 
 35 
were independently associated 
















Key findings/ Summary 




65 (9) A sample of 
outpatient women 
with PTSD and 
SUD. 
• DSM-IV  
• Traumatic History 
Questionnaire 













harm, SI, SA(s) (past 
three months) 
• 13.8% engaged in SIB, 10.8% 
attempted suicide, and 7.7% 
had both SIB and attempted 
suicide (n=21 total).  
• Of these 21 women, 61.9% 
reported drinking alcohol or 
using drugs immediately before 
or during the SA/self-harm 
episode.  
• Recent history of SIB and/or 
attempted suicide were more 
likely to have diagnoses of 
AUD and polysubstance 
dependence and less likely to 








2,219 (NR) IDUs 15-30 yrs 
old recruited from 





SI, SA(s), and suicide 
plan(s)(6-months) 
• 68.9% of participants were 
using heroin daily. 
• In the past 6-months, receiving 
money for sex was associated 
with recent SA(s) 
• Daily heroin, speedball, 
marijuana, or IDU was not 
associated with recent SA(s)  
• Polydrug use was significantly 
associate with recent SA 
  















SA(s), intentional OD 
(lifetime, past 6-months) 
• 17% reported an intentional OD 
(n=42); 67% reporting at least 
one in the past 6-months. 
• Primary reasons for intentional 
OD included: relationship 
breakdown (3/9), family 
problems (2/9), and treatment 
discharge 
• Survivors of recent intentional 
ODs reported using a 
statistically significantly higher 


















Key findings/ Summary 




433 (217) Treatment seeking 
outpatients 
recruited between 















SA(s) (lifetiome) • Patients reporting serious and 
non-serious SAs had earlier 
onset of OUD and tobacco 
smoking.  
• Women were less likely to have 
a serious SA when they 
reported any history of MOUD.  
• Women with current mood 
disorder and OUD were less 


















488 (488) Individuals, 18-63 
yrs old receiving 
SUD treatment. 













nonviolent suicide (FY 
2002-2006) 
• OUD and polysubstance use 
were associated with greater 
likelihood of nonviolent 
suicide.  
• Logistic regression analyses 
found that among those who 
died by suicide, cocaine, OUD, 
and multiple SUDs were all 
associated with greater risk of 
nonviolent compared to violent 
suicide. 
• Patients with OUD who died by 
suicide have an odds ratio of 
0.76 of using violent means 
compared to an odds ratio of 























Key findings/ Summary 




607 (406) HIV+ (n=204) and 
HIV- (n=202) 
patients with 
history of heroin 
IDU in methadone 
treatment. 






• Item 9 of the Beck 
Depression 
Inventory-II  
Heroin, alcohol SI (past 2 weeks) • Factors significantly associated 
with current SI included being 
unmarried or unemployed, 
having a lifetime (past) history 
of major depression, or lifetime 
alcohol use disorder or heroin 
use disorder.  
• Among treated IDUs (n = 407), 
past history of major 
depression, or past AUD, and 
higher BDI-II total score were 
associated with current 
suicidality  
• Longer duration of IDU and 
poor social support were also 
significantly associated with 
current suicidality  
• Multivariable predictors of 
suicidality were HIV-related 
stress, social support, and prior 
history of major depression.  
• Suicidality among HIV- treated 
IDUs, was best predicted by 
prior history of major 
depressive disorder and prior 
history of AUD. 
• Prior major depression 
increased risk by 6-fold and 












• DSM-IV  Alcohol, heroin, 
overall drug use 
SA(s) (past month) • 37.0% (n=40) had a history of 
SA.  
• Childhood trauma 
questionnaire scores were 
significantly higher among 
patients with a history of SA 
than patients without a history 
of SA.  
• Patients with a SA also had a 
greater likelihood of meeting 
DSM-IV criteria for another 



















Key findings/ Summary 




122 (61) Patients with 
OUD. 
• DSM-IV  









SA(s) (lifetime), SI 
(current) 
• 37.7% (n=23) of the heroin 
dependent group had a personal 
history of SA; the most 
frequent method was 
intentional heroin OD, oral 
medication OD and cutting.  
• History of SA was associated 
with females, had younger age 
of first substance use, and 
OUD. 
• Number of SAs was 
significantly associated with 
number of previous detox 
admissions and number SAs 
among family. 
• Subjects with OUD, 9 had 
current SI. 
• Patients with current SI did not 
have higher rates of OD, but 
they did have significantly 








37,933 (7,468) 2009 National 
Survey on Drug 
Use and Health 
(NSDUH). 
• DSM-IV  Non-medical 
prescription 
opioids 
SI, SA(s) (past 12-
months) 
• Approximately 7% of the 
former nonmedical prescription 
opioid users (n = 310), 11% of 
the persistent users (n = 287), 
and 9% of the recent-onset 
users (n = 178) reported SI 
compared to the 3% of never 
users who reported ideation. 
• A greater proportion of 
persistent (17%) and recent-
onset (19%) users with ideation 
also reported SA as compared 
with former and never users. 
• 23% of nonmedical users with 
past-year prescription opioid 
disorder reported SI 
• Individuals with OUD had 
more than threefold increased 



















Key findings/ Summary 




60 (27) Nondepressed, 
male inpatients 











• Higher rates of OUD were 
found in people who reported 
SIB. 
• Individuals with SIB had 
significantly higher rates of 
OUD, risk of isolation, the 
number of life events, anger 
trait and anger expression, 
personality disorder, number of 
substance use problems, and 













1,125 (726) Individuals 
receiving MOUD 
treatment. 






SI (lifetime), persistent 




• Cases were recruited from 
opioid maintenance treatment. 
• Controls were recruited from 
the community in the same 
geographic area as the 
treatment centers. 
• Female cases were significantly 
more likely to attempt suicide 
prior to the onset of heroin use 
compared to male cases (68% 
vs 46%). 
• Cases who reported a lifetime 
SA were significantly more 
likely to meet DSM-IV criteria 
for dependence for each drug 
class examined and psychiatric 
disorders assessed.  
• OUD was not a significant risk 
factor for SAs over and above 
























Key findings/ Summary 




966 (686) Individuals with 
and without OUD. 







behavior (SIB), Both SIB 
& SA(s) (lifetime) 
• Female cases were significantly 
more likely to report a history 
of SIB compared to male cases.  
• The SIB group were 
significantly more likely to be 
female, younger, completed 
more than 10 years of 
schooling, report every 
childhood maltreatment 
subtype, meet criteria for 
alcohol dependence, and 
criteria for dependence on more 
lifetime drug classes.  
• The SIB and SA were more 
likely to report multiple 
lifetime SAs compared to those 
in the SA only group and had a 
significantly increased risk for 
screening positively for BPD.  


















SI, suicide plan(s), SA(s) 
(lifetime) 
• Of those with lifetime SI (n= 
77), plans for suicide were 
reported by 62.3% (n=48), and 
75.3% (n=58) reported SAs. 
• Each unit increase in childhood 
emotional neglect score and 
number of potentially traumatic 
life events, the adjusted odds of 
lifetime SI increased by 9% and 
13%, respectively.  
• History of depression, anxiety, 
childhood emotional neglect, 
and the number of lifetime 
traumatic events were 
significantly associated with 
higher odds of SI. 
• For women histories of 
depression and anxiety 
remained independently 
associated with lifetime SI 
among women 
• For men, childhood emotional 
neglect and number of lifetime 
traumatic events were 



















Key findings/ Summary 








1995 and 2003. 
• DSM-IV 
• Drug Addiction 
History Rating 
Scale (DAH-RS) 











SI (past week) • Suicidal thoughts during the 
past week were reported by 199 
patients (29.1%).  
• SI did not correlate with 
patterns of heroin use (presence 
of periodic self-detoxification 
vs. uninterrupted use), 
frequency of intake (daily vs. 
sporadic), age of first substance 
use or age at first treatment.  
• A significant association was 
present between duration of 
addiction and SI. 
• Odds of SI were higher for 
patients receiving welfare 
benefits (OR = 1.69), with 
bipolar  spectrum disorder (OR 
= 1.42), the unemployed (OR = 
1.37), those with early onset  of 
OUD (OR = 1.36), those living 
alone (OR = 1.33), and those 













196 (36) Bereaved SUD 
patients, abstinent 
for at least 30-
days. 
• DSM-IV-TR  
• Spanish version of 
the Risk of Suicide 
(RS) (Plutchick et 




Suicide Risk • There was no relationship 
between main SUD diagnosis 
and risk of suicide.  
• Subjects who injected or 
nasally administered drugs had 
a higher risk of suicide than 

























Key findings/ Summary 
Neale (2000)/ 
Scotland 
Mixed-Methods 77 (62) Individuals with 










accidental OD (lifetime) 
• 49% of the 77 participants 
reported suicidal thoughts or 
feelings (suicidal intent) prior 
to their current OD.  
• A significant association was 
found between intentional 
overdosing and self-reported 
history of mental health 
problems (p, 0.001).  
• Mean number of types of drug 
taken prior to OD was 2.3 for 
individuals with an intentional 
OD and 2.1 for accidental ODs. 
• Most commonly used drugs 
prior to OD were heroin (46 
respondents); alcohol (23 
respondents); temazepam (18 
respondents); diazepam (17 
respondents); and methadone 
(16 respondents).  
• Heroin was the most frequently 
used drug by both intentional 
(n=16) and accidental ODs 
(n=30) but was significantly 
more likely to be used in the 
accidental than in the 
intentional incidents. 
  




6,744 (NR) Criminal justice 
clients with SUDs. 
• Addiction Severity 
Index 


















• Cox regression analyses found 
death from a fatal accidental 
OD was associated with use of 
heroin and cannabis; male 
gender was marginally 
significant. 
•  Cox regression analysis found 
that death from 
injury/intoxication of 
undetermined intent was 
positively associated with use 
of heroin, binge drinking 
alcohol, and previous 
psychiatric hospitalization.  
• Sensitivity analysis found that 
death from intoxication of 
undetermined intent was 
positively associated with use 
of heroin and binge drinking 
 43 
alcohol; negatively associated 
with depression.  
• Death from suicide was 
positively associated with 



















Key findings/ Summary 
Oyefeso et al. 
(2008)/England 









Opioids Patterns and prevalence 
of self-injurious 
behavior; predictors of 
self-injurious behavior 
(SIB) (lifetime, past 12-
months) 
• 69% of patients reported using 
heroin in the past 30-days 
• 39 patients endorsed SIB; 
lifetime SIB prevalence of 49.  
• 10 patients endorsed the 
question “Have you hurt 
yourself on purpose in the last 
12 months?” prior year 
prevalence of 13%.  
• Reasons for SIB among opiate 
addicts was affect-regulation 
followed by self-punishment.  
• Most frequently reported SIB 
types were cutting (74%), nail 
biting (51%), chewing inside 
mouth (44%), and self-beating 
(36%). 
• The most frequently cited 
reasons for SIB were to cope 
with emotional pain (84%), to 
express hatred for self (68%), 
to express feelings of 
helplessness and powerlessness 
(63%) and to stop feelings of 
emptiness, numbness and 
depression (58%).  
• 76% of patients reported 
persistent drug and/or alcohol 
























Key findings/ Summary 





2,750 (2,750) OUD inpatients 
admitted between 
1990 and 2010. 
• DSM-III & DSM-
IV (heroin 
dependence) 
• ICD-9 & ICD-10 
(suicide mortality) 
Heroin Suicide mortality 
(January 1,1990-
December 31, 2010) 
• Suicides among inpatients with 
heroin dependence, had a 16-
fold greater standardized 
mortality ratio (SMR=16.2) 
compared to the general 
population and the highest 
SMR among all specified cause 
of death categories.  
• Mean interval from the index 
admission to suicide was 5.8 
years (SD = 4.2).  
• Methods include:  hanging(n = 
27), charcoal burning/gases 
other than in domestic use (n = 
17),drugs/poisons (n = 14), 
jumping from a high place (n = 
3), drowning (n = 2), cutting (n 
= 2), gases in domestic use (n = 
1), and others (n = 3); no one 
used firearms.  
• Multivariable analysis found 
that SA at index admission and 
lifetime depressive syndrome 
were significantly associated 




























Hospitalized SA(s) (past 
12-months) 
• No relationship between 















































Prevalence of lifetime 
non-fatal ODs and SAs 
(baseline, 5-year follow-
up) 
• 43% (n =85) reported being 
hospitalized once or several 
times because of ODs.  
• There was a weak relationship 
between OD and SA(s). 
• Daily use of opiates and 
number of months in inpatient 
treatment were significant 
correlates of OD.  
• Clients who had spent up to 1 
year altogether in inpatient 
treatment had 4.17 times 
greater chance of an OD than 
clients who had not been in 
treatment  
• Clients who had spent 1 year or 
more in inpatient treatment had 
8.74 times greater chance of 
OD than clients without 
inpatient treatment.  
• 47% (n=94) of clients reported 
having one or more SAs.  
• Individuals with SA reported 
greater consumption of alcohol 
(17 vs. 13 liters pure alcohol) 
and a more frequent use of 
opioids (43% daily use vs. 
32%) in the last 6-months. 
• Individuals with a SA had more 
frequent use of 
benzodiazepines, reported more 
ODs, had more in- and 
outpatient treatment and spent 




























Key findings/ Summary 











• DSM-IV  Heroin SA(s) (lifetime); OD(s) 
(past 12-months; 
lifetime) 
• 58% of participants had 
experienced a heroin OD (OD), 
with 28% occurring in the 
preceding 12-months.  
• In the 12-months prior to 
interview, the RR group was 
more likely to have ODd in 
than the MT, DTX and NT 
groups. 
• 37% of the sample reported a 
SA, 14% having made an 
attempt in the past 12-months 
and 6% in the preceding month.  
• Prevalence of attempted suicide 
in the past 12-mos did not 
differ by treatment modality. 
• Females were significantly 
more likely to have a SA in the 






2,051 (1,367) National sample 











other substances  
Prevalence of non-fatal 
ODs and SA(s); 
predictors of covariation 
between OD and SA(s) 
(lifetime) 
• 45.5% reported having 
experienced one or more ODs.  
• About 70% who experienced an 
ODs had two or more 
• 16% reported having 9+ ODs  
• 32.7% reported having made 
one or more SAs,  
• Among those who reported 
SAs, 56.1%reported 2+ 
attempts. 
• Odds of having attempted 
suicide were six times higher 
among those who had 
experienced ODs (OR=6.3  
• The number of SAs was also 
positively and significantly 
associated with the number of 
ODs. 
• Individuals with both SAs and 
ODs were characterized as 
older; more often homeless; 
displayed poor social 
functioning and mostly 
maintaining social relations in 
the drug scene; daily use of 
opiates, alcohol and 
tranquilizers; HIV risk-taking 
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behavior, having more 
psychiatric problems 
(depression and anxiety) and 
















Key findings/ Summary 
Roy (2002)/USA Case-Control 
Study 
246 (246) OUD patients with 
and without SA.  
• DSM-IV   Opioids, alcohol, 
cocaine 
SA(s), first- and second-
degree relative history of 
suicide (lifetime) 
• 105 of the 246 patients with 
OUD reported a lifetime SA.  
• 21 patients attempted suicide 
by deliberate heroin OD with 
intent to die, and 12 of those 
made at least one additional 
attempt using other methods.  
• OUD patients with history of 
SA had significantly higher 
childhood trauma scores for 
emotional abuse, physical 
abuse, sexual abuse, emotional 
neglect, and physical neglect 
than compared to OUD patients 
without history of suicide. 
Significantly more patients with 
SA had a history of cocaine 
dependence and alcohol 
dependence. 
•  Significantly more people with 
SA had history of major 
depressive disorder and higher 
ASI composite scores. 
• Of the 105 patients with a SA, 
31 had a family history of 
suicidal behavior. 
• Multivariable analysis also 
found that neuroticism with 
significantly and independently 
associated with SA and had 


























Key findings/ Summary 
Roy (2010)/USA Case-Control 
Study 





SA(s) & familial history 
of suicide (lifetime) 
• 207 of the 527 OUD patients 
(39.3%) attempted suicide.  
• Patients who had attempted 
were younger than those who 
had no history of SA and a 
majority were female.  
• Significant predictors of SA 
were family history of suicidal 
behavior, alcohol or cocaine 
dependence, and receiving 
antidepressant medication. 










• Urine toxicology 
(confirm opioid 
use at intake) 
Opioids Characteristics of SA(s), 
familial history of SA 
• 27% of patients (10 men and 
11 women) made their first SA 
before they experienced 
heroin.  
• Women made more attempts 
and they resorted to non-
heroin drug ODs more 
frequently. 




48 (48) Outpatients 
receiving 
treatment for 
SUDs, with a 
history of opioid 
IDU.  
 
Heroin Non-intentional OD(s); 
intentional OD(s) or 
SA(s) (lifetime, past 12-
months) 
• 54% (n=26) of patients had 
experienced a heroin OD in the 
past, 10 had only overdosed 
once;16 had multiple ODs. 
• 60%(n=29) patients had a 
history of suicidal thoughts 
• 26 had a suicide plan; plans 
include:  6 had thoughts about 
heroin OD, 14 had considered 
OD of other drugs, 3 had 
thought of cutting, 2 of 
shooting and 1 of jumping.  
• 35% (n=17) patients had made 
SAs in the past. Methods of 
attempt include: 2 took a heroin 
OD, 12 took an OD of other 
drugs, 2 by cutting, and 1 by 
jumping.  
• History of heroin OD, half 
(13/26) made a SA at some 
time in their lives. 
• OD of heroin was not a 
common method for attempting 
suicide: of the 13 subjects who 
had a history of both heroin OD 

















Key findings/ Summary 




470 (470) Adults admitted to 
an inpatient 
treatment. 








SI, SA(s) (6, 12, 18, & 
24-months, lifetime) 
• No significant associations 
between frequency of recent 
alcohol, heroin, 
benzodiazepines or cocaine use 
and SAs, whether or not 
depressive symptoms were 
present 
• Alcohol, heroin, 
benzodiazepines or cocaine 
were not significantly 
associated with either SI or SA.  
Abbreviations: 
BPD=Borderline Personality Disorder; DSM=Diagnostic and Statistical Manual; OD=Overdose; OUD= Opioid Use Disorder; SA= Suicide Attempt; SI= Suicidal Ideation; SIB= Self-Injurious 
Behavior(s); SUD=Substance Use Disorder 
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TABLE 2.2: Quality Assessment and Rating of Systematic Review Studies 
 
2.2A). Evaluation of Case-Control Studies 
 
Author          
(Pub year) 






















Case-Control Y Y N Y Y Y Y N Y Y NR Y   Good 
Kazour   
(2016) 


































Abbreviation definitions:  Y=Yes; N=No; NR=Not Reported; NA= Not Applicable; CD= Cannot Determine; CL=CheCLlist Item 
Key for Case-Control Studies: 
CL1. Was the research question or objective in this paper clearly stated?  
CL 2. Was the study population clearly specified and defined? 
CL 3. Was the participation rate of eligible persons at least 50%?  
CL 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied 
uniformly to all 
participants?  
CL 5. Was a sample size justification, power description, or variance and effect estimates provided?  
CL 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?  
CL 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?  
CL 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous 
variable)?  
CL 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?  
CL 10. Was the exposure(s) assessed more than once over time?  
CL 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?  





2.2B). Evaluation of Cohort and Cross-Sectional Studies 
  
Author         
(Pub year) 




Cross Sectional Y Y Y Y Y N N Y Y N Y NA NA Y Good 
Baykara  
(2018) 
Cross Sectional  Y Y NR Y N N N N Y N Y N NA N Poor 
Best  
(2000) 





Y Y Y Y Y Y Y N Y NA Y N NA Y Good 
Borges  
(2000) 
Cross Sectional  Y Y Y Y Y N N N Y N Y N NA Y Fair 
Bradvik  
(2007) 
Cross Sectional  Y Y Y N N N N N Y N Y N NA N Poor 
Cheek  
(2016) 
Cross Sectional  Y Y Y Y Y N N N Y N Y N NA Y Good 
Chen  
(2009) 





Y Y CD Y N N N N Y N Y N N Y Fair 
Darke  
(2001) 
Cross Sectional  Y Y CD Y N N N Y Y N Y N NA Y Fair 
Darke  
(2004) 
Cross Sectional  Y Y Y Y N N N Y Y Y Y N NA Y Good 
Darke 
(2010) 
Cross Sectional  Y Y CD Y N N N Y N Y Y N NA Y Good 
Darke  
(2012) 





Y Y Y Y N Y Y Y Y Y Y N N Y Good 
 
2.2B). Evaluation of Cohort and Cross-Sectional Studies (Continued) 
 










Cross Sectional  Y N CD Y N N N N Y N Y Y NA Y Fair 
Gilmore  
(2018) 
Cross Sectional  Y Y NR Y N N N N Y N Y N NA Y Good 
Hakansson 
(2010) 
Cross Sectional  Y Y N Y Y N N NA N N Y N Y N Good 
Harned 
(2006) 















































Cross Sectional Y Y CD Y N N N Y Y N N N NA Y Good 
Icick 
(2017) 
Cross Sectional Y Y CD Y N Y Y Y Y N Y CD NA Y Good  
Kalyoncu 
(2007) 
Cross Sectional  Y N CD CD N N N N Y N Y NR NA Y Poor 
Kuramoto 
(2012) 
Cross Sectional  Y Y Y Y NA N N Y Y N Y N NA Y Good 
Lavania 
(2012) 
Cross Sectional  Y Y CD Y Y N N N Y N Y CD NA Y Good 
Marchand 
(2017) 
Cross Sectional  Y  Y CD Y N N N N Y N Y CD NA Y Fair 
Maremman
i (2007) 
Cross Sectional  Y Y NR NR N N N N Y N Y NR NA CD Poor 
Masferrer 
(2016) 
Cross Sectional  Y Y Y Y Y N N N Y N Y NR NA Y Good 
Olsson  
(2016) 
Cohort  Y Y Y Y NA Y Y NA Y N Y N Y Y Good 
Oyefeso 
(2008) 





Y Y CD Y NA Y Y N Y N Y N NA Y Good 
Ravndal 
(1999) 
Cohort  Y Y NR Y N Y Y N Y N Y NR N CD Fair 
Ross  
(2005) 
Cohort Study  Y Y NR Y N Y Y Y Y Y Y CD NR NR Good 
Rossow  
(1999) 
Cross Sectional  Y Y N Y CD N N N Y Y N Y NR NA Fair 
Vingoe  
(1999) 























































Cohort  Y Y NR Y N Y Y N Y N Y N NR Y Fair 
Neale     
 (2000) 
Mixed Methods  - - - - - - - - - - - - - - N/A 
Abbreviation definitions:  Y=Yes; N=No; NR=Not Reported; NA= Not Applicable; CD= Cannot Determine; CL=CheCLlist Item 
Key for Cross Sectional/Cohort Studies: 
CL1. Was the research question or objective in this paper clearly stated?  
CL 2. Was the study population clearly specified and defined? 
CL 3. Was the participation rate of eligible persons at least 50%?  
CL 4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied 
uniformly to all 
participants?  
CL 5. Was a sample size justification, power description, or variance and effect estimates provided?  
CL 6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?  
CL 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?  
CL 8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous 
variable)?  
CL 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?  
CL 10. Was the exposure(s) assessed more than once over time?  
CL 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?  
CL 12. Were the outcome assessors blinded to the exposure status of participants?  
CL 13. Was loss to follow-up after baseline 20% or less?  




3 Feasibility and Acceptability of Safety Screening Among Patients Receiving Addiction 
Treatment  
3.1 Abstract 
Background: Premature mortality associated with opioid-related overdose and suicide is a 
significant public health problem in the United States (U.S.). Approximately 20–30% of 
individuals with opioid use disorder have a history of both suicide attempt and unintentional 
opioid overdose. Objective: The objective of this study is to evaluate the feasibility of a 
standardized screen for suicide and overdose among patients receiving addiction treatment. 
Design: A cross-sectional study was conducted using a convenience sample of patients (n=113) 
recruited from two inpatient treatment programs. Methods: A modified version of the Patient 
Safety Screener (mPSS) was used to screen for suicidal ideation, suicide attempt, and overdose. 
The screen was administered in-person during treatment, and results were linked to 
administrative clinical data. Subjects (n=108) and members of their clinical care team (n=20) 
completed a screening acceptability survey. A positive mPSS was recorded if a patient reported 
suicidal ideation in the past two weeks, a suicide attempt, and/or an overdose in the past six 
months. Results: Fifty-eight percent of subjects had a positive mPSS screen, and 30.3% reported 
suicidal ideation, suicide attempt, and overdose. Subjects and clinical staff reported that it was 
acceptable to screen for suicide attempt(s) and overdose(s). About a third of the clinical staff 
reported concerns about administration time (n=7) and impact on workflow (n=6). Conclusions: 
Both suicide and overdose are important patient safety factors that should be incorporated into 
treatment and discharge planning. The findings of this study support simultaneously screening 
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for suicide and overdose in OUD inpatient treatment settings. Future research needs to determine 























3.2 Introduction  
Premature mortality associated with opioid-related overdose and suicide are significant 
public health problems in the United States (U.S.) (Bohnert and Ilgen, 2019; Cunningham et al., 
2018; Oquendo and Volkow, Rockett et al., 2016; 2018; VanHouten et al., 2019). In 2018, there 
were 46,802 opioid-related overdoses (14.3 per 100,000) and 48,344 (14.2 per 100,000) suicides 
reported in the U.S. (Wilson, 2020; Xu et al., 2020). Previous research has estimated that 20–
30% of individuals with opioid use disorder (OUD) have reported a history of both a suicide 
attempt(s) and unintentional opioid overdose(s) (Darke et al., 2015; Maloney et al., 2010). 
People with OUD have elevated mortality rates, with suicide being one major contributor to 
premature mortality (Darke et al., 2011; Degenhardt et al., 2011; Darke et al., 2007; Wilcox et 
al., 2004). Additionally, overdose also plays a significant role in morbidity and mortality among 
individuals with OUD (Bohnert et al., 2010; Darke et al, 2015; Ravndal & Vaglum, 1999). While 
previous reports have estimated that 25% of opioid overdose deaths are intentional (Oquendo & 
Volkow, 2018), this is likely an underestimate given that suicide rates due to poisoning are 
underreported by approximately 30% (Donaldson et al., 2006). Furthermore, with the true 
proportion of non-fatal ODs identified as intentional being unknown, there exists a relationship 
between suicide and overdose that is difficult to ascertain.  
Several studies have examined individuals with a history of both unintentional overdose(s) 
and suicide attempt(s) (Maloney et al., 2010; Rossow and Lauritzen, 1999). Subjects with this 
joint history manifest worse psychological and social functioning, as well as more severe drug-
related problems than those without a history of both unintentional overdose(s) and suicide 
attempt(s) (Bohnert et al., 2010). Ravndal and Vaglum found that 47% of clients in addiction 
treatment reported at least one suicide attempt, and 43% had at least one overdose-related 
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hospitalization (1999). Patients with a history of suicide attempt(s) were more likely to report 
polydrug use, non-fatal overdose, and higher healthcare utilization (Ravndal & Vaglum, 1999). 
The higher clinical severity observed among patients with a history of suicide and overdose 
reflects that these individuals need a broader range of services and intensive case management 
(Bohnert et al., 2010). Despite evidence of the overlap between overdose and attempted suicide, 
clinical screening and intervention have not been integrated. 
Accurate identification of patients with a history or at risk of suicide and overdose is critical 
for treatment planning. In higher acuity treatment settings, there may be regulatory requirements 
to conduct universal suicide screening; however, there are no regulations to screen for a history 
of non-fatal overdose, and it is unknown whether overdose history is routinely assessed. The 
Joint Commission has recognized the importance of identifying suicide risk as part of routine 
clinical care and emphasizes the documentation of suicide assessments (both positive and 
negative findings), particularly in behavioral health care settings (The Joint Commission, 2016). 
However, suicide documentation in electronic medical records (EMRs) is often inconsistent or 
incomplete (Tanguturi et al., 2017). An estimated 83% of suicide decedents utilized healthcare in 
the year prior to their death, and 24% had a documented mental health diagnosis within 4-weeks 
prior to death (Ahmedani et al., 2014). Missing or incomplete suicide documentation in the EMR 
may have led to missed opportunities to deliver prevention services. The mental health and 
addiction treatment systems are not integrated, and at a regulatory level, this may discourage 
simultaneous screening for overdose and suicide. Some behavioral health programs may be 
unable to treat patients with active suicidal ideation because their physical environment does not 
meet the requirements to ensure safety. Individuals with substance use disorders (SUDs) 
frequently have co-occurring mental health problems (Swendsen et al., 2010; Harris & 
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Barraclough, 1997), which can be very difficult to distinguish in the early phase of treatment, 
especially as withdrawal causes dysphoria. As many as 40% of patients seeking SUD treatment 
have a history of suicide attempt(s) (Roy & Janal, 2007; Roy, 2009; Roy, 2010). Patients 
frequently present with depressive symptoms and significant functional impairments that may 
not only drive them to seek treatment, but also put them at higher risk for suicidal behavior 
(Yuodelis-Flores et al., 2015).  
The feasibility of suicide screening has been demonstrated in different healthcare settings, 
including emergency departments (EDs) and primary care settings (Boudreaux et al., 2013; 
Boudreaux et al., 2016; King et al., 2009; Lish et al., 1996). Standardized suicide screening 
improves identification of at-risk individuals previously not identified (King et al., 2009; 
Boudreaux et al., 2016). The Emergency Department-Safety Assessment and Follow-up 
Evaluation (ED-SAFE), a quasi-experimental multisite clinical trial, found that standardized 
suicide screening resulted in a nearly two-fold increase in patient endorsement of any past or 
present intentional self-harm ideation or behavior (i.e. suicide risk detection) (Boudreaux et al., 
2016). While presumably suicide screening is occurring in addiction treatment programs, there 
are no psychometrically validated overdose screening assessments, and it is unlikely that 
overdose history documentation specifies intentionality. Given the magnitude of the opioid and 
suicide epidemics (Rockett et al., 2019; Hedegaard et al., 2020), and due to evidence that 
prevention interventions can reduce the risk of suicide (Zalsman et al., 2016) and overdose 
(Irvine et al., 2019), integrated screening and risk evaluation are warranted. The objective of this 
study is to evaluate the feasibility of an integrated overdose and suicide standardized screen, in 
the context of inpatient treatment for individuals with OUD. This feasibility study includes 





A cross-sectional study was conducted, and patient data was collected using a structured 
in-person interview, a web-based survey (screening acceptability), and extraction of data from 
administrative clinical records. Clinician data was collected using a web-based survey on screen 
acceptability. Both participating patients and clinical staff provided written informed consent.  
Study Setting 
Patients with an OUD were recruited from two treatment programs associated with a 
university-based health care system. One site was an acute inpatient dual-diagnosis unit that 
treats individuals who: 1) need medically managed detoxification and 2) are a danger to 
themselves or others (i.e. suicidal ideation/suicide attempt and/or homicidal ideation or actions). 
The second site was an inpatient treatment program that offered detoxification services and a 28-
day residential program; subjects were only recruited from the residential unit.  
Data Collection 
Study Sample.  
A convenience sample of patients were recruited from the acute inpatient unit starting in 
February 2019, and recruitment at the residential unit began in August 2019. Recruitment 
concluded at both sites in October 2019. Patients were included in the study if they were 
currently being treated at a recruitment site, had a confirmed diagnosis of OUD (communicated 
the attending physician or electronic medical record (EMR) documentation of OUD), and were 
willing to provide written informed consent. Patients were excluded if they were: 1) unable to 
read and write in English, 2) deemed not psychiatrically stable (i.e. no medical decision making 
capacity, active hallucinations, or homicidal ideation as determined by the attending physician), 
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3) met the definition of incarceration (i.e. known to have a current warrant for their arrest, 
pending criminal charges, currently wearing an electronic ankle monitoring device, and/or 
mandated to treatment by law enforcement), 4) under the age of 18 years, or 5) were pregnant. 
Participation was completely voluntary, and compensation was not provided for study 
participation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
Clinical staff, who were actively employed during the study period, were recruited from 
the two sites. Staff recruitment occurred from December 2019 through February 2020. Staff were 
eligible for study participation if they: 1) provided treatment (i.e. conducted therapy groups, 
distributed medications, conducted therapeutic interventions, or were a treatment provider) to 
patients enrolled in the study, 2) attended treatment team meetings, and 3) were willing and able 
to provide written informed consent. Administrative staff without patient contact were ineligible 
to participate. 
Measures 
Administrative Clinical Database. 
Administrative clinical data was extracted from a patient reported outcomes monitoring 
system used at both recruitment sites, details of which are provided elsewhere (Winstanley et al. 
2020). Variables extracted included sex, race (white/non-white), ethnicity, education (less than 
high school, high school graduate/GED, or some college+), employment (employed full/part-
time or unemployed), number of times arrested (lifetime), substance use history, and the adverse 
childhood experiences (ACEs) instrument. Substance use history included lifetime use (yes/no), 
age of first use, and route of administration for tobacco, alcohol, cocaine, marijuana, heroin, 
prescription opioids (illicit use), buprenorphine (illicit use), methamphetamines, and 
benzodiazepines. Other clinical characteristics extracted included lifetime injection drug use 
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(yes/no), number of overdoses (lifetime), and age of first overdose. The 17 ACE items were 
categorized as mental health problems (2 items); alcohol or drug use (2 items); emotional, 
physical or sexual abuse (6 items); neglect (3 items); physical or emotional abuse by a significant 
other (1 item), and family dissolution (3 items). These categories were summed to generate a 
total score.  
Modified Patient Safety Screener.  
Subjects were administered a modified version of the Patient Safety Screener (PSS), 
developed by Boudreaux and colleagues (2013, 2015). A positive PSS is defined as suicidal 
ideation in the past two weeks or a suicide attempt in the past six months. The modified PSS 
(mPSS) included a sixth (new) question on previous drug overdose. The first question assesses 
depressed mood, and this item is not included in screen scoring. The second question was “over 
the past two-weeks, have you had thoughts of killing yourself?” and the response options are 1) 
yes, 2) no, 3) patient unable to complete, or 4) patient refused. The third question asked, “In your 
lifetime, have you ever attempted to kill yourself?”  Subject responses included: 1) yes, 2) no, 3) 
patient unable to complete, or 4) patient refused. If the subject responded in the affirmative, a 
follow-up question asked, “when did this happen?”  There were six possible responses: 1) within 
the past 24 hours (including today), 2) within the past month (not including today), 3) between 
one and six months ago, 4) more than six months ago, 5) patient was unable to complete, or 6) 
patient refused. The overdose question, added for this study, was modeled to match the suicide 
question just described. However, the words “attempted to kill yourself” were replaced with 
“overdose.” The mPSS took approximately five minutes to administer, and a positive mPSS was 
defined as suicidal ideation in the past two weeks, a suicide attempt in the past six months, 
and/or overdose in the past six months. The ‘in the past 24-hours and ‘past month’ response 
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options were combined because subjects were not interviewed within the first 24 hours of their 
admission. For a subject with a positive mPSS screen, the attending physician and the subject’s 
primary therapist were notified of the result via encrypted e-mail with a PDF of the subject’s 
mPSS attached. If subject told a study team member that they were an immediate danger to 
themselves or others, the unit lead (i.e. charge nurse or lead therapist) was notified immediately 
and the attending physician was paged.  
Patient Acceptability Survey.  
Subjects who completed the mPSS were asked to complete a web-based patient 
acceptability survey. Subjects were asked to rate the extent to which they agreed or disagreed 
with six statements about comprehension, time burden, relevance of the screen to treatment, 
invasiveness of the screening questions, willingness to complete the screen questions in the 
future, and usefulness of the screening. The responses used a five-point Likert scale ranging from 
strongly disagree to strongly agree. Due to the distribution of responses, they were recoded as: 1) 
disagree, 2) neither disagree nor agree, or 3) agree. The survey took approximately ten minutes 
to complete.  
Staff Acceptability Survey.  
The staff acceptability survey comprised ten closed-ended and five open-ended questions. 
Twenty-four staff were eligible to participate in the study. Four were unable to be contacted 
because they were no longer employed at either site and their contact information was 
inaccessible. A web-based survey was sent via e-mail to 20 staff who had provided written 
informed consent. Staff who were unresponsive to the email request to complete the online 
survey, were provided a hard copy of the survey. The staff survey comprised questions on 
respondent age, job title, number of years working in current position, and number of years 
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working in addiction treatment. Staff responded to four statements using a five-point Likert scale 
ranging from strongly disagree to strongly agree: 1) information provided by the safety screen is 
useful in clinical practice, 2) information provided on the safety screen changed how I treated the 
patient, 3) the safety screen placed an unnecessary burden on the clinical staff, and 4) the safety 
screen placed an unnecessary burden on the patient. Responses were recoded as agree, neither 
agree nor disagree, or disagree. The survey included a question on which patients should receive 
the mPSS, also referred to as the “safety screen” (all patients/high risk patients only/done at 
physician discretion/none). The open-ended questions included whether the screening 
information changed how patients were treated, improvements that would make the screen more 
useful, aspects of the screen that were most useful, potential barriers to implementing the screen 
into routine clinical practice and whether the screen should be integrated into clinical practice.  
Statistical Analysis 
Descriptive statistics were used to summarize the sociodemographic and clinical 
characteristics of the sample, as well as the acceptability surveys. Medians were reported for 
variables that were not normally distributed, with the exception of age. Statistics were reported 
for the overall sample, as well as by recruitment site to determine whether important clinical 
differences were associated with recruitment site. Recruitment site differences were determined 
using Pearson’s chi-square tests for categorical variables, t-test for means, and the Mann-
Whitney U (Wilcoxon Ranksum) test to compare medians. Quantitative data analysis was 
conducted using Stata/SE 15.0 analytical software (StataCorp, 2017). Statistical significance was 
defined as p £ 0.05. 
 The open-ended questions in the staff acceptability survey were analyzed using a 
thematic analysis approach (Biggerstaff & Thompson, 2008; Vaismoradi et al., 2013; Wagstaff 
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& Williams, 2014). The open-ended responses were coded and then combined into two 
overarching themes of advantages and disadvantages of the screen. These themes were used to 
subcategorize responses from clinical staff and were based on procedures outlined for previous 
qualitative methods (Vaismoradi et al., 2013). The qualitative analysis was hand coded by two 
members of the study team (ANS and ELW), and the study protocol was approved by the West 
Virginia University Institutional Review Board (IRB). 
3.4 Results 
Two hundred and eight patients were pre-screened for study eligibility. Ninety-five patients 
were excluded, and 113 provided written informed consent. The primary reasons for exclusion 
included inability to provide informed consent for mental health reasons (29.5%, n=28), patient 
discharge or leaving treatment before screening (25.3%, n=24), pregnancy among female clients 
(15.9%, n=15), declining to participate (13.7%, n=13), legal issues/current arrest warrant (8.4%, 
n=8), failure to comply with study procedures (4.2%, n=4), and complications due to 
detoxification (3.2%, n=3). Seventy-two patients (63.7%) were recruited from the acute inpatient 
unit and 41 (36.3%) were recruited from the residential treatment facility (Figure 3.1).  
The overall sample was predominantly non-Hispanic (95.6%), white (95.6%) and male 
(64.3%). The majority of the sample had at least a high school diploma or GED (46.9%), and 
23.9% of participants were employed in the past 30 days (Table 3.1). Clinical characteristics of 
the sample are reported in Table 3.1. There were no statistically significant differences in 
demographic or clinical characteristics by recruitment site, except subjects at the acute inpatient 
program were, on average, 3.3 years older than those recruited from the residential program 
(Table 3.1). 
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Overall, 58.4% of the subjects screened positive on the mPSS, 38.1% had suicidal ideation in 
the past two weeks, 46.3% had a suicide attempt(s) in the past six months and 39.7% had 
overdosed in the past six months. Subjects recruited from the acute inpatient program were 
significantly more likely to report suicidal ideation in the past two weeks (50.0% versus 17.1%; 
p<0.01) and a suicide attempt in the past six months (29.7% vs 5.9% or 11.8%, p=0.02) than 
subjects recruited from the residential program.  
The patient acceptability survey had a 95.6% response rate (n=108). Overall, 18.5% of 
respondents found the screen time consuming. Additionally, 4.6% found it difficult to understand 
and 6.4 % would not want to complete another screening. Furthermore, 5.6% were 
uncomfortable with the questions on the mPSS. Finally, 4.6% of subjects did not find the mPSS 
useful and 6.5% did not understand how the screening related to their treatment. Across all of the 
items in acceptability survey, 14-23% endorsed ‘neither agree nor disagree.’  Screen 
acceptability did not vary by recruitment site (see Table 3.3).  
Twenty staff completed the acceptability survey, with a response rate of 83.3%. The mean 
age of staff respondents was 35.0 years (SD=10.1). A quarter of the staff was physicians, another 
quarter drug and alcohol technicians, 20.0% were clinical therapists or counselors, 20.0% were 
social workers, 5.0% were nurses, and 5.0% were clinical coordinators. Ninety-five percent of 
staff agreed the mPSS provided useful information, 45.0% found it provided information that 
changed how they treated the patient, 70.0% reported it did not place an unnecessary burden on 
the patients, 85.0% thought all patients should receive the mPSS, 100% of staff thought the 
assessment was useful in clinical practice, and 95.0% thought the mPSS should be integrated into 
standard clinical practice.  
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Open-ended items in the staff acceptability survey were categorized as follows:  1) treatment 
change, 2) improvements to increase usefulness in clinical practice, 3) aspects of the safety 
screen found most useful, 4) extant barriers to clinical implementation, and 5) integration into 
clinical practice. Overall analysis of the open-ended response data found that respondents 
reported 12 advantages and 9 disadvantages. Most respondents found the results of the mPSS to 
be informative (n=17) and stated that “It allows for clinicians to make more educated, evaluated 
decisions,” and “I think it is a good tool to measure where the patient is mentally when they 
arrive to the facility.” 
Other advantages of the mPSS included the ability to convey risk (n=8), assess the patient 
(n=7), evaluate safety (n=7), the completeness of the assessment (n=5), its usefulness (n=4) in 
clinical practice, and informing patient history (n=3; Figure 3.2). For instance, the clinical 
therapists and social workers conveyed:  
“This helps better understand this person's past coping mechanisms.” 
“The safety of the guest is the utmost importance. This is another tool to ensure that the most 
is being done to keep them safe.” 
“It provides more detail about the patients history so we can tailor treatment to the individual 
and reduce risk.” 
Other advantages mentioned by respondents included reporting comorbidities (n=2), clinical 
management (n=1), efficiency (n=1), individual care (n=1), and relatability (n=1). 
The most frequently reported disadvantage of the mPSS was time to complete (n=7). This 
problem was compounded by other issues, such as workflow (n=6), communication (n=4), 
patient resistance (n=2), and concerns about patient re-traumatization (n=2). For example: 
“While some of these questions may be asked/answered in the admissions process, it would be 
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nice to have them definitely in their chart and always in one spot.” While, other staff members 
provided the following feedback: “Takes a long time to administer, was sometimes triggering to 
the patients.” A complete list of themes is depicted in Figure 3.2. 
3.5 Discussion  
This study found that nearly 60% of subjects receiving inpatient OUD treatment had suicidal 
ideation, suicide attempts and/or overdose. A fifth of the subjects had a history of only 
overdose(s), whereas a third had current suicidal ideation and a history of overdose(s) and 
suicide attempt(s). Lifetime suicide attempt(s) (46.3%) in this study was consistent with existing 
research (Roy, 2010; Roy, 2002; Ravndal & Vaglum 1999); however, the prevalence of a 
lifetime overdose (60.2%) was still higher than reported in previous research of patients seeking 
addiction treatment (Ross et al., 2005). This difference speaks to the point that, while suicide 
history is important to address in addiction treatment, screening for overdose plays an equally 
important role in understanding patient history as a whole.  
The most positive feedback received was for comprehension of screening questions. Given 
that more than half of subjects had a high school education or less, it is important that 83.3% of 
subjects reported that the mPSS questions were easy to understand. Furthermore, although 
patients in both clinical settings were required to be psychiatrically cleared by the attending 
physician, some patients were receiving various pharmaceutical interventions to treat their 
addiction or psychiatric conditions. Particularly for patients in the acute inpatient settings, some 
patients may have experienced the effects of detoxification and possibly were still adjusting to 
their new environment (Rapeli et al., 2006). Thus, it is essential to have a screening tool with 
easily comprehended questions. A minority of respondents (18.5%) reported that the screen was 
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time consuming; while the survey question was in reference to administration time for the mPSS 
only, subjects might interpret it as the time to complete the entire research interview.  
Despite clinical concerns that patients may be uncomfortable completing a standardized 
screen on suicide and overdose, 94.4% of patients were comfortable with the screen. A previous 
literature review found most studies reported that only a small minority of patients, who 
participated in trauma-focused research, experienced distress (Legerski & Bunnell, 2010). 
Moreover, most studies reported that negative feelings dissipate quickly, and that the great 
preponderance of patients participating in research feel rewarded (Legerski & Bunnell, 2010). A 
study by Biddle and colleagues measured the emotional state of adult and adolescent 
participants, with a history of self-harm or suicidality, before and after interviews on their 
personal experiences (Biddle et al., 2013). They reported that over 50% of participants found 
talking about their experiences beneficial. Affirming previous findings, 73.2% of patients in our 
study reported the mPSS was useful and 78.7% understood how the questions pertained to their 
current treatment. Nevertheless, it is important to consider that the screening questions on 
potentially traumatic events may cause patient distress (LeFevre, 2014). In these instances, it is 
important to address patient concerns, provide them with the appropriate resources, and allow 
them time to process their emotions before ending the interview (Espisto, 2019; LeFevre, 2014) 
All staff reported that the mPSS was useful in clinical practice and was a minimal burden to 
patients. All but one agreed that the instrument should be integrated into standard clinical 
procedures. However, the clinical staff did not administer the screen, and it was not administered 
upon treatment entry. If clinicians had to administer the screen, overall acceptability may have 
been lower. Conversely, if the screen was administered at intake and integrated into the standard 
workflow, then it may have had higher clinical utility. There was disagreement on whether the 
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screening results changed how the patient was treated, and this variation may be partially 
explained by the respondent’s clinical role and involvement in treatment planning. 
The staff acceptability survey also included six open-ended response questions. Several 
disadvantages were frequently reported by the staff. Seven reported administration time as a 
disadvantage. This involvement may actually reflect disruption to clinical workflow and indicate 
a barrier in terms of the division of labor regarding which staff members would be tasked with 
administering the mPSS in the future. Furthermore, workflow could be impacted by several 
features of the screen, such as when the mPSS is administered and how the results are 
communicated. For the current study, mPSS was administered during intake or the patient’s 
unstructured free time; however, the results were often not communicated to the therapist prior to 
interview. Although results were provided to the clinical staff, results were not recorded in the 
EMR or communicated at the same point in treatment. This knowledge gap resulted in potential 
duplication of work and redundancy. It bolsters the case for having the mPSS incorporated 
directly into the patient’s EMR and readily accessible for care team review. Conversely, another 
common theme was that staff treat all patients uniformly irrespective of background. This could 
partially be due to the large number of staff members completing the survey, who did not have 
one-on-one patient contact, but rather interacted with patients in group settings. One such group 
was drug and alcohol technicians, who comprised 25.0% of survey respondents. Regarding 
barriers to implementation, time was the biggest disadvantage reported by staff members. 
Overall, the mPSS was thought to be efficient in providing a concise reporting tool for conveying 
safety risk. However, patients who screened positive would ultimately require longer 
assessments. This means a longer time commitment for the patient and for the staff member 
administering the detailed suicidal ideation, suicide attempt, and/or overdose assessment—
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depending on the initial mPSS result. However, despite these barriers and concerns, 95.0% of 
staff reported the mPSS should be integrated into standard clinical practice. 
Limitations 
As the study sample was recruited from an inpatient population, the results may not 
generalize to other treatment modalities. Likewise, the majority of the subjects recruited for this 
study was predominantly white and non-Hispanic, and results might not generalize to more 
diverse patient populations. In order to integrate this instrument into clinical practice, members 
of the clinical team would need to administer the screening to patients or have the screen self-
administered by patients. Integration may require more time from the staff to debrief with 
patients that become distressed. Although it is ideal to administer the mPSS at intake to help 
inform treatment planning, the accuracy of the results may be compromised if the patient arrives 
intoxicated or has not established rapport with the treatment team.  
Future Directions 
Overall, additional research is needed to determine the optimal timing of mPSS 
administration and to establish the test-retest validity of the instrument. Furthermore, additional 
research needs to be conducted to establish the prospective validity of the tool and if the tool 
changes clinical practice and/or the provision of prevention services. Stricter criteria for when to 
administer the mPSS should be established to obtain consistent results, and/or criteria set for re-
screening at various points throughout the inpatient stay to address fluctuations in suicidality. 
The next step would be to test the mPSS among patients enrolled in outpatient treatment 





Based on the current findings from this study, concurrent screening for overdose and 
screening is acceptable and warranted. Through a dual screening procedure, this may increase 
the clinical awareness of the overlap between overdose and suicide among patients with OUD. 
For this reason, suicidal behaviors warrant more clinical and research attention in the addiction 
field (Yuodelis-Flores et al., 2015), and support the need to for all clients receiving addiction 
treatment services to also be screened and monitored for suicidality and overdose. This finding 
indicates screening for both suicide and overdose is an important clinical contributor to overall 
patient safety assessment and provides crucial information for treatment and discharge planning. 
Both patients and staff found the mPSS informative and appropriate for assessment and approved 
of the application of instrument to the clinical setting. In general, the greater the burden of risk 
factors, the higher the likelihood for suicide attempt or death by suicide. The information 
gathered in this study shows that the mPSS is an appropriate screening tool to address these 
issues. Additional research is necessary to determine whether screening improves provision of 
services and reduces self-injurious behavior.  
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Table 3.1: Study Sample Demographics 






Mean Age (years), (SD)* 35.2 (9.2) 36.4 (9.0) 33.1 (9.3) 0.02 
Sex (% Male) 72 (63.7) 47 (65.3) 25 (61.0) 0.65 
White (%) 108 (95.6) 68 (94.4) 40 (97.6) 0.65 
Non-Hispanic (%) 108 (95.6) 68 (94.4) 40 (97.6) 0.65 
Employed (%) 27 (23.9) 21 (29.2) 6 (14.6) 0.08 
Education (%)    0.42 
     Less than High School 18 (15.9) 9 (12.5) 9 (22.0)  
     High School Grad/GED 53 (46.9) 35 (48.6) 18 (43.9)  
     Some College/College Grad 42 (37.2) 28 (38.9) 14 (34.1)  
Lifetime Arrests (Median) 5.0 5.0 4.0 0.23 
Ever Used, Lifetime (% Yes)     
     Tobacco 112 (99.1) 71 (98.6) 41 (100.0) 1.00 
      Alcohol 112 (99.1) 71 (98.6) 41 (100.0) 1.00 
     Cocaine 102 (90.3) 63 (87.5) 39 (95.1) 0.32 
     Marijuana 111 (98.2) 70 (97.2) 41 (100.0) 0.53 
     Heroin 100 (88.5) 62 (86.1) 38 (92.7) 0.37 
     Prescription Opioids 104 (92.0) 68 (94.4) 36 (87.8) 0.28 
     Illicit/Non-Medical Buprenorphine Use 49 (43.4) 29 (40.3) 20 (48.8) 0.38 
     Methamphetamines/Amphetamines 98 (86.7) 61 (84.7) 37 (90.2) 0.57 
     Benzodiazepines 74 (65.5) 61 (84.7) 37 (90.2) 0.64 
Mean age of First Use (Years), (SD)     
     Tobacco* 13.1 (5.0) 12.9 (5.2) 13.6 (4.7) 0.62 
      Alcohol* 13.8 (6.9) 13.9 (8.4) 13.7 (3.1) 0.71 
     Cocaine* 19.0 (4.9) 18.8 (5.0) 19.4 (4.7) 0.69 
     Marijuana* 14.3 (3.9) 14.7 (4.5) 13.6 (2.4) 0.18 
     Heroin* 24.8 (9.3) 24.4 (9.1) 25.4 (9.6) 0.61 
     Prescription Opioids* 18.3 (6.4) 18.6 (7.0) 17.6 (5.3) 0.56 
     Illicit/Non-Medical Buprenorphine Use* 25.6 (9.1) 25.9 (10.2) 25.2 (7.5) 0.71 
     Methamphetamines/Amphetamines* 27.4 (8.6) 27.5 (8.3) 27.3 (9.2) 0.71 
     Benzodiazepines* 20.4 (8.2) 21.4 (8.6) 18.9 (7.3) 0.27 
Ever Inject Drugs (%Yes, Lifetime) 88 (77.9) 58 (80.6) 30 (73.2) 0.36 
Mean Age First Injection Drug Use (SD)* 25.1 (8.4) 25.6 (8.9) 24.1 (7.4) 0.68 
Median Number of Lifetime Overdoses 1.0 1.0 1.0 - 
Median Number of Overdoses (Past Six-
Months)  3.0 3.0 2.5 0.64 
Mean Age First Overdose (Years) (SD)* 26.5 (10.3) 27.1 (9.9) 25.4 (11.2) 0.33 
ACE Total Domain Score 4.8 (1.8) 4.8 (1.7) 4.8 (1.9) 0.91 
Table 3.1: For ease of comparison ages were reported as means. However, variables designated with an “*” did not follow a normal 
distribution therefore medians were compared using Wilcoxon rank-sum tests. Unless otherwise noted variables were compared using chi-

























Table 3.2: Modified Patient Safety Screen (mPSS) Responses 








 n % n % n %  
Depression in past two-weeks (Yes) 101 89.4 64 88.9 37 90.2 1.00 
Suicidal Ideation in past-two weeks (Yes) 43 38.1 36 50.0 7 17.1 <0.01 
Lifetime Suicide Attempt (Yes) 54 47.8 37 51.4 17 41.5 0.31 
Most Recent Suicide Attempt       0.02 
     Within the last month  12 22.2 11 29.7 1 5.9  
     Between 1-6 months ago  13 24.1 11 29.7 2 11.8  
     More than 6 months ago  29 53.7 15 40.6 14 82.4  
Ever Overdose (Yes) 68 60.2 43 59.7 25 61.0 1.00 
Most Recent Overdose       0.15 
     Within the last month  14.0 20.6 12 27.9 2 8.0  
     Between 1-6 months ago  13.0 19.1 8 18.6 5 20.0  
     More than 6 months ago  41.0 60.3 23 53.5 18 72.0  






    Suicidal Ideation Only 5 7.58 5 9.62 0 0.0 0.57 
    Suicide Attempt Only 4 6.1 3 5.8 1 7.1 1.00 
    Overdose Only 13 19.7 8 15.4 6 35.7 0.09 
    Suicidal Ideation + Suicide Attempt 11 16.7 10 19.2 1 7.1 0.43 
    Suicidal Ideation + Overdose 7 10.6 6 11.5 1 7.1 1.00 
    Suicide Attempt + Overdose 6 9.1 5 9.6 1 7.1 1.00 
    Suicidal Ideation + Suicide Attempt + Overdose 20 30.3 15 28.9 5 35.7 0.62 
Table 3.2: Comparisons were made using chi-squared or Fisher’s exact tests where appropriate. Statistical significance was set at p£0.05. Additional details 
























Table 3.3: Patient Acceptability Questionnaire Responses 









The self-harm screen was time consuming.    0.99 
     Disagree 63 (58.3) 40 (58.0) 23 (59.0)  
     Neither disagree nor agree 25 (23.2) 16 (23.2) 9 (23.1)  
     Agree 20 (18.5) 13 (18.8) 7 (18.0)  
The questions in the screening questionnaire were hard to understand.    0.78 
     Disagree 90 (83.3) 56 (81.2) 34 (87.2)  
     Neither disagree nor agree 13 (12.0) 9 (13.0) 4 (10.3)  
     Agree 5 (4.6) 4 (5.8) 1 (2.5)  
In the future I would not want to complete another self-harm screen.    0.29 
     Disagree 83 (76.9) 56 (81.2) 27 (69.2)  
     Neither disagree nor agree 18 (16.7) 9 (13.0) 9 (23.1)  
     Agree 7 (6.4) 4 (5.8) 3 (7.7)  
The questions on the self-harm screen made me uncomfortable.    0.35 
     Disagree 85 (78.7) 51 (73.9) 34 (87.2)  
     Neither disagree nor agree 17 (15.7) 13 (18.8) 4 (10.3)  
     Agree 6 (5.6) 5 (7.3) 1 (2.5)  
The questions asked in the self-harm screen were not useful.    0.71 
     Disagree 79 (73.2) 49 (71.0) 30 (76.9)  
     Neither disagree nor agree 24 (22.2) 17 (24.6) 7 (18.0)  
     Agree 5 (4.6) 3 (4.4) 2 (5.1)  
I do not understand how the self-harm screen relates to my treatment.    0.57 
     Disagree 85 (78.7) 53 (76.8) 32 (82.1)  
     Neither disagree nor agree 16 (14.8) 10 (14.5) 6 (15.4)  
     Agree 7 (6.5) 6 (8.7) 1 (2.5)  
Table 3.3: Comparisons were made using chi-squared or Fisher’s exact tests where appropriate. Statistical significance was set at p£0.05. Additional 
details are described in the methods section. 
† Five study participants did not complete the survey, two interviews were discontinued before the patient acceptability survey by the interviewer for 










Table 3.4:  Staff Characteristics and Acceptability Questionnaire Responses 
 
3.4A) Staff Characteristics (n=20) 
  
Age (Mean (years)), (SD) 35.0 (10.1) 
Job Title (%), (n)  
     Drug & Alcohol Technician 25.0 (5.0) 
     Physician 25.0 (5.0) 
     Social Worker 20.0 (4.0) 
     Clinical Therapist/Counselor 20.0 (4.0) 
     Nurse 5.0 (1.0) 
     Clinical Coordinator 5.0 (1.0) 
Years Worked in Current Position (mean), (SD) 3.4 (4.8) 
Total Years in AOD* Field (mean), (SD) 9.2 (8.0) 
3.4B) Acceptability Questionnaire Responses (Frequency) (%)   
 
The information provided by the safety screen is useful to clinical practice.   
     Disagree 1 (5.0) 
     Neither disagree nor agree 0 (0.0) 
     Agree 19 (95.0) 
Information provided on the safety screen changed how I treated the patient.  
     Disagree 3 (15.0) 
     Neither disagree nor agree 8 (40.0) 
     Agree 9 (45.0) 
The safety screen places unnecessary burden on the clinical staff.  
     Disagree 16 (80.0) 
     Neither disagree nor agree 4 (20.0) 
     Agree 0 (0.0) 
The safety screen places unnecessary burden on the patient.  
     Disagree 14 (70.0) 
     Neither disagree nor agree 6 (30.0) 
     Agree 0 (0.0) 
Which patients should receive safety screening?  
    All patients 17 (85.0) 
    High risk patients only 1 (5.0) 
    Done at the discretion of the physician 2(10.0) 
    None 0 (0.0) 
Is the self-harm assessment useful for clinical practices (% Yes) 20 (100.0) 
Should the patient safety screen become part of clinical practice? (% Yes) 19 (95.0) 
4C) Staff Acceptability Open-Ended Questions (Frequency) (%)   
 
Please explain how the information did or did not change how you treated the patient. 10 (50.0) 
What improvements could be made to the safety screen to make it more useful in clinical practice? 7 (35.0) 
What aspects of the safety screen did you find the most useful? 13 (65.0) 
What barriers might prevent the patient safety screen from being implemented into routine clinical practice? 11 (55.0) 
Should the patient safety screen become part of clinical practice? 12 (60.0) 
Table 4: Comparisons were not made between treatment facilities due to small sample size recruited for this portion of the study. 
Open-ended question responses are reported in Figure 2. Additional details are provided in the methods section. 
*AOD=Alcohol or Drug 
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4 Distinguishing Clinical Factors Associated with Unintentional Overdose, Suicidal 
Ideation, Suicide Attempt, and Opioid Use Disorder 
 
4.1 Abstract 
Background: Both suicide and opioid use disorder (OUD) represent significant threats to public 
health. Premature mortality due to opioid-related overdose and suicide continues to rise in the 
United States. Objective: The objective of this study is to examine the clinical factors that may 
distinguish three patient groups: 1) unintentional overdose(s) (OD), 2) suicidal ideation or 
suicide attempt(s) (SI/SA), and 3) suicidal ideation or suicide attempt and unintentional overdose 
(SI/SA/OD). Design:  This was a cross-sectional study conducted in a subset of subjects 
recruited from two inpatient addiction treatment facilities (n=66). Methods: Subjects were 
categorized as having a history of unintentional OD (n=13); SI/SA (n=33); or SI/SA/OD (n=20). 
Multinomial logistic regression models were used to determine whether adverse childhood 
experiences, self-injurious behaviors, substance use history, overdose history, and past year 
stressful life events were differentially associated with history of SI/SA/OD. Results: Overall, 
19.7% of the study sample reported an overdose, while 50.0% reported SI/SA, and 30.3% 
reported SI/SA/OD. Subjects in the overdose group were more likely to have used heroin in the 
24-hours preceding their most recent overdose compared to either the SI/SA or SI/SA/OD 
groups. In the multivariable model, subjects with history of SI/SA had higher adverse childhood 
experience scores and more subjects with history of SI/SA endorsed childhood physical abuse 
and teen dating violence. Conclusions: Overall, history of overdose is distinct from suicidal 
ideation and attempt. However, patients with SI/SA/OD appear to have greater clinical severity. 
More thorough evaluation of drugs involved in overdose and history of self-injury may help 
distinguish future risk and better inform treatment planning. More thorough evaluation of drugs 
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involved in overdose and history of self-injury may help distinguish future risk and better inform 
treatment planning. 
4.2 Introduction 
Premature mortality due to opioid-related overdose and suicide represent a significant threat 
to public health in the United States (U.S.) across all age groups; both of which are leading 
causes of injury death that have continued to rise over the past decade (Connery et al., 2019; 
Bohnert & Ilgen, 2019; Oquendo and Volkow, 2018). However, since drug overdose is the third 
most frequently used method of suicide the overlap between unintentional overdose and suicide 
is often murky (Centers for Disease Control and Prevention, 2017). Large population studies 
confirm that individuals with OUD, who survive an opioid-related overdose, remain at 
significantly elevated risk for repeat, fatal overdose (Olfson et al., 2018b) and death by suicide 
(Bogdanowicz et al., 2016; Olfson et al., 2018a). Multiple clinical factors are associated with 
opioid-related overdose and/or suicidal behavior among individuals with OUD, including use of 
heroin (Dai et al., 2019; Darke et al., 2015; Hakansson et al., 2008; Park et al., 2018), history of 
injection drug use (IDU) (Bohnert et al., 2011; Hakansson et al., 2008), polysubstance use 
(Bohnert et al., 2011; Bradvik et al., 2009; Darke et al., 2004; Jonsson et al., 2007), 
benzodiazepine use (Bohnert et al., 2017; Darke, 1996; Hakansson et al., 2008; Jones and 
McAninch, 2015), co-occurring psychiatric disorder (Bohnert et al., 2017; Darke et al., 2004, 
2015; Maloney et al., 2007), history of sexual/physical trauma (Bohnert et al., 2011; Darke et al., 
2004; Stein et al., 2017), violence directed toward others (Bohnert et al., 2011; Hakansson et al., 
2008), and history of suicide attempt or persistent suicidal ideation (Darke et al., 2004, 2007; 
Hakansson et al., 2008; Maloney et al., 2007; Pan et al., 2014).  
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A 2010 review by Bohnert and colleagues reported that overdose and suicide are distinct, yet 
potentially related events. This review cited that the primary association between overdose and 
suicidal behaviors was based upon a single study by Darke and Ross in 2001, which found that 
individuals who had overdosed were also more likely to have attempted suicide, compared to 
those who had never overdosed. However, this association was largely explained by overdose as 
a method of suicide attempt, and when intentional overdose cases were removed from the 
analysis, it was no longer statistically significant (Darke & Ross, 2001). Furthermore, when 
examining individuals with non-fatal overdoses and suicide attempts separately, both groups had 
worse psychological and social functioning as well as more severe drug-related problems 
(Bohnert et al., 2010). Patients with a history of both overdose and suicide attempt have 
significantly impaired functioning and increased severity in substance use, which necessitates 
delivery of higher intensity services compared to their peers without either previous suicide 
attempt(s) or overdose (Bohnert et al., 2010). Individuals with OUD who attempt suicide by drug 
overdose are more likely to use prescription medications, cocaine, alcohol, and sedatives; 
whereas, heroin is more likely to be used in unintentional overdoses (Bohnert et al., 2010; Pfab 
et al., 2006; Ravndal and Vaglum, 1999; Schifano et al., 2006). Existing research has not 
adequately accounted for precursory events and behaviors, such as trauma and self-injury, which 
may contribute to the intersection between overdose and suicide. Poor social functioning, 
psychiatric decline, and higher severity of substance use are overlapping risk factors for overdose 
and suicide that require further investigation.  
Nonfatal overdoses are associated with increased acute care utilization and elevated risk of 
subsequent mortality. Between 2005 and 2014, opioid-related emergency department visits in the 
U.S. nearly doubled, while hospital admissions related to opioid use increased by nearly two-
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thirds (Weiss et al., 2016). This has resulted in increased clinical interest in characterizing the 
subsequent risk of overdose and non-overdose related causes of death (Olfson et al., 2018). 
Previous research has shown that OUD is associated with an elevated risk of premature mortality 
(Pierce et al., 2015). In the year after a nonfatal opioid overdose, patients died at approximately 
24 times the rate of the general population (Olfson et al., 2018). Beyond stabilizing patients after 
nonfatal opioid overdoses, clinicians in acute care settings have opportunities to initiate 
medications for treatment of opioid use disorder and engage patients in ongoing treatment, harm 
reduction, or specialty addiction services (D’Onofrio et al., 2017). After a nonfatal overdose, 
men, but especially women, were at exceptionally high risk of suicide. In a recent study of 
veterans, the association between OUD and suicide was significantly stronger among women 
(Bohnert et al., 2017). The rate of suicide during the first-year post overdose, for women (29.3 
per 10 000 person-years), resembled the rate of suicide following the year after SIB (30.9 per 10 
000 person-years) (Olfson et al., 2017). Although SIB and nonfatal overdose are distinct 
behaviors that utilize different prevention strategies, they can co-occur within an individual, and 
careful clinical assessment may be necessary to delineate them. A high risk of suicide after 
nonfatal opioid overdose underscores the importance of careful mental health assessment with 
appropriate follow-up for selected patients (Oqueno et al., 2017). Understanding these risks 
could inform efforts to provide preventive and potentially lifesaving medical care after a nonfatal 
opioid overdose and better integrate mental health care with the treatment of OUDs. 
The objective of this study is to examine the clinical profiles of three patient groups: 1) 
unintentional overdose (OD), 2) suicidal ideation and suicide attempt (SI/SA), and 3) suicidal 
ideation, suicide attempt, and unintentional overdose (SI/SA/OD). These objectives were 
accomplished by examining the age of onset of substance use, age of initiation of SIB, last 
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episode of self-injury, ACE domain scores, and past year stressful life experiences for each of 
the three groups. Previous research has found an association between higher ACE scores and 
younger age of onset of opioid use, recent injection drug use, and lifetime overdose (Stein et al., 
2017). Likewise, studies have reported that higher ACE scores are associated with increased risk 
of suicidal ideation and a suicide attempt (Dube et al., 2001; Thompson et al., 2019). Based on 
previous research, it is hypothesized that perceived stressful life events will be associated with 
SI/SA while ACE domain scores will be an overlapping factor in both SI/SA (Chen et al., 2010) 
and the unintentional overdose groups (Stein et al., 2017). Furthermore, subjects with more 
recent episodes of SIB will represent the group with a more severe behavioral profile (i.e., 
SI/SA/OD) who engage in more high-risk behaviors and require higher levels of care.  
4.3 Methods 
Study Design 
This was a cross-sectional study conducted in a subset of subjects recruited as part of a 
larger inpatient study. The original study recruited inpatients with OUD to test the acceptability 
of an integrated suicide and overdose screen. 
Setting 
A convenience sample of patients with an OUD was recruited from two treatment 
programs associated with a university-based health care system in West Virginia. One facility is 
an 18-bed acute inpatient dual-diagnosis unit that treats individuals who: 1) need medically 
managed detoxification and 2) are a danger to themselves or others (i.e., suicidal ideation/suicide 
attempt and/or homicidal ideation or actions). The second site is a 28-day residential addiction 






Study Sample.  
The parent study recruited subjects (n=113) between February 2019 and October 2019. 
Patients were included in the study if they had an opioid use disorder, were psychiatrically 
stable, and were over the age of 18 years old.  
Participation was voluntary, and subjects were not compensated for study participation. 
Only subjects that self-reported suicidal ideation in the past two weeks, an overdose in the past 
six months, and/or a suicide attempt in the past six months, were included in this study (n=66).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
Measures 
Administrative Clinical Data 
Demographic (sex, race, ethnicity, education, and number of lifetime arrests), clinical 
characteristics, substance use history, ACE sub-scores, and ACE total score were extracted from 
an administrative clinical database (Winstanley et al., 2020). Race was recoded into a 
dichotomous variable (white/non-white); because the sample was predominantly white and had 
little variability. Employment was also recoded into a dichotomous variable (employed full/part-
time or unemployed). Education was recoded into a categorical variable (less than high school 
education, high school graduate/GED, or some college/college graduate). Substance use history 
was recoded as lifetime use (yes/no) for tobacco, alcohol, cocaine, marijuana, heroin, 
prescription opioids, illicit/non-medical use of buprenorphine, methamphetamines, and 
benzodiazepines. This history also included age of first use for each substance endorsed by the 




Adverse Childhood Experiences.  
The clinical administrative database included a modified version of the adverse childhood 
experiences (ACEs) questionnaire (Winstanley et al. 2020). ACEs measure different types of 
childhood adversities experienced before age 18 and higher scores are associated with overdose 
and suicidal behaviors (Chen et al., 2010; Stein et al., 2017; Thompson et al., 2019). The 
modified ACE has 17 items that were grouped into the following categories of adverse 
experiences: mental health problems; alcohol or drug use; emotional, physical or sexual abuse; 
neglect; physical or emotional abuse by a significant other (teen dating abuse), and family 
dissolution. A total ACE score was generated by summing the number of categories endorsed.  
Self-Harm Assessment 
This assessment was a 30-minute face-to-face interview, which included information on 
drugs used prior to last overdose, past year stressful life events, self-harm behaviors, suicidal 
ideation, and suicide attempts. Global mental health was assessed using the Patient Reported 
Outcomes Measurement Information System (PROMIS) item, “In general, how would you rate 
your mental health, including your mood and ability to think?” This was rated on a 5-point Likert 
scale from poor to excellent (Cella et al., 2010). Due to the distribution of responses, “excellent,” 
“very good,” and “good were collapsed into one category to create the following three 
categories: 1) “good,” 2) “fair,” and 3) “poor.”  Two items from the Beck scale for suicidal 
ideation (Beck et al., 1979). The first item was “how you have been feeling over the past week, 
including today” and the response options were 1) “I have a moderate to strong wish to live,” 2) 
“I have a weak wish to live,” or 3) “I have no wish to live” and it was recoded as 
moderate/strong wish to live or weak/no wish to live. For the second item asked how he or she 
was feeling in the past week and the response options were 1) “I would try to save my life if I 
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found myself in a life-threatening situation,” 2) “I would take a chance on life or death,” or 3) “I 
would not take the steps necessary to avoid death if I found myself in a life-threatening 
situation.” 
Overdose Assessment 
For this study, an opioid overdose was defined as “when you cannot breathe and cannot 
wake up without medical help.”  Irrespective of when the overdose occurred, subjects who 
endorsed ever having an overdose, were asked 10 questions that queried details about their most 
recent overdose. They were asked to report their age of first overdose and the number of 
overdoses they have experienced in their lifetime. Subjects were asked for the date of their most 
recent overdose, the location where the overdose occurred and, if it was the first time they 
experienced an overdose (yes/no). Subjects were also asked if their most recent overdose was an 
accident (yes/no). They were further asked if they used alcohol (yes/no), prescription drugs 
(yes/no), street drugs (yes/no), and/or over the counter medications (yes/no) in the 24-hours prior 
to their overdose. For each category that the subject reported “yes,” he/she was asked to specify 
the name of the substance used. Drugs and medications used were categorized as antidepressants, 
antipsychotics, benzodiazepines, cocaine, prescription opioids, heroin, methamphetamines, and 
sedatives. Subjects were asked if naloxone was used to revive them (yes/no); did anyone do 
anything to help you when you last overdosed (yes/no); if measures were taken to help you 
during your last overdose, what were these helpful measures (open-ended); if counseling or 
overdose education was provided after the overdose (yes/no); and if the patient would like any 




Life Events Checklist 
Stressful life events were measured using a modified Life Events Checklist (LEC), which 
measures life events that adults often find difficult or stressful in the past year. These events 
included experiencing a natural disaster, fire or explosion, transportation accident, serious 
accident, exposure to a toxic substance, physical assault, assault with a weapon, sexual assault, 
unwanted sexual experience, combat exposure, captivity, severe human suffering, sudden violent 
death, sudden accidental death, serious injury or harm the person inflicted on another person, 
and/or any other very stressful event or experience (Weathers et al., 2013). The original 17-item 
LEC was modified by the inclusion of an additional item on dissolution of a romantic 
relationship in the past year. This item was added because research has found that ending of a 
romantic relationship is a stressful event that is associated with suicide attempt (Dragisic et al., 
2015; Heale et al., 2003). The LEC has five response items and subjects were instructed to select 
all options that applied for each event over the course of their lifetime. For this study, subjects 
were instructed to only consider these events for the past year instead of over the course of their 
lifetime and to only choose one response instead of choosing all responses that apply (Weathers 
et al., 2013). For the purposes of this study, a total score was generated to reflect the number of 
stressful life events in the past year. Each response was assigned a numeric value: (a) it happened 
to you personally=3, (b) you witnessed it happen to someone else=2, (c) you learned about it 
happening to someone close to you=1, (d) you’re not sure if it fits (coded as missing), or (e) it 
doesn’t apply to you=0. For the questions on sudden violent death (for example, a homicide or 
suicide) and sudden accident death, witnessing it happen to someone else was scored as 3 and 
learning about it as 2, since these events could not directly happen to the subject or participant. 
The LEC items were summed to generate a total score, which ranged from 0-54.  
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Self-Injurious Behaviors Assessment 
The non-suicidal self-injury section of the Self-Injurious Thoughts and Behaviors 
Interview (SITBI-SF) (Nock et al., 2007) was used to measure SIB and evaluate lifetime suicidal 
ideation. Lifetime suicidal ideation was measured using the first three questions from the SITBI-
SF suicidal ideation section. Self-injurious behaviors were measured using all questions from the 
SITBI-SF included in the non-suicidal self-injury portion of the interview. The questions related 
to suicide plan, attempt, and gesture were omitted for the purposes of this research study.  
Suicidal Behaviors Assessment 
Additional suicidal behaviors were evaluated using the suicide behaviors questionnaire-
revised form (SBQ-R) (Osman et al, 2001). This tool uses four questions that ask patients if they 
have ever thought about or attempted suicide, how often they have thought about suicide in the 
past year, if they ever told another person they might attempt suicide, and how likely is it they 
would attempt suicide in the future. For the last question, the response options are never, no 
chance at all, rather unlikely, unlikely, likely, rather likely, and very likely. For analytic 
purposes, the categories of never/no chance at all, rather unlikely/unlikely, and likely/rather 
likely were collapsed into four response options. SBR-Q scoring is calculated using the original 
responses, without alteration of the response categories. This tool is used to identify suicide risk 
and risk behaviors, yielding a score ranging from 3-18, among inpatients (Osman et al., 2001), A 
score of greater than or equal to eight classified inpatients as having increased suicide risk with 
80% sensitivity (true-positivity) and 91% specificity (true-negativity).  
Data obtained during the patient interview was entered into a REDCap (Remote 
Electronic Data Capture) database, using an encrypted tablet computer. If an immediate crisis 
was identified (i.e., patient discloses intent to harm themselves, others, or discloses current 
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suicidal ideation/plan), the attending physician and charge nurse were notified immediately. The 
duration of the total screening and interview time was approximately 40-50 minutes. 
Data Analysis 
The outcome variable was based on patient self-report of suicidal ideation in the past two 
weeks, overdose in the past six months, and/or suicide attempt in the past six months. This 
information was used to create the following mutually exclusive categories:1) unintentional 
overdose(s) only (no suicidal ideation in the past two weeks or attempt in the past six months); 2) 
suicidal ideation (past two weeks), suicide attempt (past six months) (SI/SA); and 3) 
unintentional overdose, suicidal ideation, and suicide attempt(s) including intentional overdose 
(SI/SA/OD). Descriptive statistics were used to summarize the sociodemographic and clinical 
characteristics of the sample. Medians were reported for variables that were not normally 
distributed, except for age. Statistical analysis employed using Pearson’s chi-square tests for 
categorical variables, ANOVAs for means, and Kurskal-Wallis H-test to compare medians with 
Dunn’s test post-hoc analysis.  
Bivariable analysis was conducted with 47 variables, including ACE category scores, 
total ACE domain score, each item of the LEC, LEC-total score, SIB behavior measures, lifetime 
overdose(s), substances used 24-hours prior to overdose, suicidal behaviors, hopelessness, and 
social support. Two multinomial logistic regression models were built (adjusted and unadjusted) 
with the SI/SA group as the base outcome. The unadjusted multinomial logistic regression 
examined ace total category score, past year work accident, past year sexual assault, past year 
combat exposure, hitting, depression in the past two weeks, and hopelessness in the past two 
weeks. The second model was an adjusted model that controlled for age and sex while examining 
ACE total category score, past year work accident, past year sexual assault, past year combat 
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exposure, hitting, depression in the past two weeks, hopelessness in the past two weeks, and 
global social support score. Data analysis was conducted using Stata/SE 15.0 analytical software 
(StataCorp, 2017).    
4.4 Results 
The sample included 66 subjects that endorsed suicidal ideation in the past two weeks, an 
overdose in the past six months, and/or a suicide attempt in the past six month; 19.7% (n=13) 
reported unintentional OD, 50.0% (n=33) SI/SA and 30.0% (n=20) SI/SA/OD. The overall 
sample was predominantly male (65.2%), white (93.4%), non-Hispanic (93.4%), unemployed 
(74.2%), and had a high school education (50.0%). There were no statistically significant group 
differences in the demographic characteristics (data not shown).     
 With respect to lifetime substance use, the only statistically significant differences were 
for cocaine and prescription opioid use. The OD group more likely to have used lifetime cocaine 
use during their lifetime (100.0%) compared to either of the other two groups (SI/SA=72.7%, 
SI/SA/OD=95.0%, p=0.02). For the overall sample, the mean age of initiation of prescription 
opioids was 18.4 years (SD=7.4). The mean age of initiation of heroin use was 24.7 years 
(SD=9.8). The SI/SA group was more likely to have used prescription opioids during their 
lifetime (97.0%) compared to the unintentional OD group (69.2%) or the SI/SA/OD group 
(90.0%, p=0.03). There were no statistically significant group differences in age of onset of drug 
use (see Table 4.1). Age of first prescription opioid use preceded onset of heroin use for all 
groups (Table 4.1). There groups did not differ in terms of recent (past month) drug use, 
injection drug use, age of first overdose or number of overdoses. With respect to substances used 
in the 24-hours prior to the most recent overdose, the five most commonly used substances were 
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heroin (67.4%), benzodiazepines (21.7%), alcohol (20.0%), prescription opioids (19.6%), and 
methamphetamine (15.2%).  
 Only two substances reported in the 24-hours prior to overdose were found to be 
statistically significantly different between groups:  antipsychotics and heroin. In the 24-hours 
prior to their most recent overdose, 30.7% of the SI/SA group reported using an anti-psychotic 
medication compared to 7.7% in the OD group and no one in the SI/SA/OD group reported using 
anti-psychotic medications prior to their last overdose (p=0.02). For the OD group, 92.3% 
reported using heroin prior to their most recent overdose compared to 30.7% of subjects in the 
SI/SA and 75.0% in the SI/SA/OD group (p<0.01) (see Table 4.1). 
The SI/SA group were more likely to report physical abuse (93.9%), than either the OD 
group (46.2%) or the SI/SA/OD group (85.0%; p<0.01). Teen dating violence was reported more 
frequently by subjects in the SI/SA (93.9%), than either the unintentional OD group (46.2%), or 
the SI/SA/OD group (85.0%; p<0.01). Overall, the SI/SSA group had a higher mean ACE score 
(mean=5.5) compared to either the OD group (mean=4.0) or the SI/SA/OD group (mean=5.0, 
p=0.04). No statistically significant differences were observed with respect to cumulative mean 
past year stressful life event (LEC score) scores or individual LEC items (Table 4.2). 
The overall sample had a median number of lifetime SIBs of 15. The OD group reported 
more lifetime SIBs (median=20) compared to the SI/SA group (median=45, p=0.05) (Table 4.3). 
No statistically significant difference was observed for mean age of first SIB, last occurrence of 
SIB, or type of SIB. with 40.6% of subjects in the SI/SA group reporting hitting themselves on 
purpose compared to 30.0% of the SI/SA/OD group and 7.7% of subjects in the unintentional 
OD group.  
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The unintentional OD group was more likely to report a moderate/strong wish to live 
(100.0%), compared to either the SI/SA (63.6%) or SI/SA/OD group (65.0%, p=0.02) (Table 
4.4). Last occurrence of suicidal ideation more frequently occurred in the past month for the 
SI/SA (90.9%) and SI/SA/OD groups (68.4%) whereas more of the unintentional OD group 
reported suicidal ideation more than a year ago (50.0%, p=0.02). There was no statistically 
significant difference in terms of mean age of first suicidal ideation or median lifetime episodes 
of suicidal ideation. There was however, a statistically significant difference between groups for 
last occurrence of suicidal ideation (p<0.01; Table 4.4). In the past month 75.8% of subjects 
reported suicidal ideation in the past month. The largest portion of subjects reporting past month 
suicidal ideation were those in the SI/SA group (90.9%), followed by the SI/SA/OD group 
(68.4%), and the unintentional OD group (16.7%; Table 4.4). Results of suicidal behaviors are 
reported in Table 4.4 and the OD group never attempted suicide; 69.7% of the SI/SA group and 
45.0% of SI/SA/OD group reported lifetime suicide attempt with hope to die (p<0.01; Table 4.4).  
The following covariates were statistically significant in the bivariable regression models:  
ACE score, work accidents (past year), sexual assault (past year), past year combat exposure, 
(past year), hitting (lifetime), depression (past two weeks), hopelessness (past two weeks), and 
global social support measures (data not shown). ACE score (p=0.05), work accident (p<0.01), 
sexual assault (p<0.01), combat exposure (p<0.01), and hopelessness (p=0.03) remained 
statistically significant in the unadjusted regression model between the OD and SI/SA groups. 
For subjects with SI/SA/OD there was a statistically significant difference for past year work 
accidents (p=0.02) and combat exposure (p<0.01) when comparted to subjects with SI/SA (see 
Table 4.5). 
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In the adjusted (adjusting for age and sex) multivariable model past year work accidents 
(p=0.02) and combat exposure (p<0.01) for subjects in the SI/SA/OD group compared to the 
SI/SA group (see Table 4.5). The OD group compared to the SI/SA group for ACE score 
(p=0.03), work accident (p<0.01), sexual assault (p<0.01), and combat exposure (p<0.01).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
4.5 Discussion 
This study found that clinical characteristics and life event differences do exist between 
treatment-seeking adults with OUD with history of SI/SA/OD. While the national focus is on 
unintentional overdoses among individuals with OUD, this study found 50% had a history of 
suicidal ideation or attempts and 19.7% had a history of only unintentional overdose. This 
indicates that greater attention be paid to factors contributing to co-morbid OUD and suicidal 
behaviors. Specifically, as it applies to substances used prior to overdose, adverse childhood 
experiences (ACEs), history of stressful life events, and self-injurious behaviors.  
Consistent with previous research (Vingoe et al., 1999; Maloney et al., 2007; Neale, 2000), 
heroin is infrequently used as a method of suicide or in self-reported intentional overdoses. Even 
in samples where heroin was reported in the overdose, it was significantly more likely to be used 
in an accidental overdose than a deliberate overdose (Maloney et al., 2007; Neale, 2000). 
Another finding, consistent with previous research, is that subjects with SI/SA/OD and SI/SA 
reported a higher prevalence of lifetime prescription opioid use than subjects with unintentional 
overdose (Hakansson et al. 2010; Roy 2002). However, rates of antipsychotic use could in part 
be explained by the large number of subjects recruited from an acute inpatient setting. Contrary 
to previous studies (Ilgen et al, 2009; Roy 2002; Roy 2010), this study found that subjects with 
unintentional overdose more frequently reported lifetime use of cocaine compared to subjects in 
the group with SI/SA. However, use of cocaine among individuals in the unintentional OD group 
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contradicts previous studies which found significant associations between cocaine use among 
individuals with OUD who attempted suicide (Ilgen et al, 2009; Roy 2002; Roy 2010). In our 
sample, the lack of association between cocaine and suicide attempt may be explained by lack of 
racial heterogeneity. Additionally, the SI/SA group reports overall less use of methamphetamine, 
cocaine, and heroin compared to the unintentional OD group, but higher use of antidepressants, 
antipsychotics, and benzodiazepines. Among subjects in the current study, in addition to heroin, 
the most frequently reported drug taken in the 24-hours prior to overdose among subjects with 
SI/SA was antipsychotics. Overall patterns of substance use may be indicative of time in 
treatment, more utilization of mental and/or behavioral healthcare services, which may limit 
access to other illicit substances. However, length of stay and healthcare utilization were not 
measured in the current study. Although specific mental health diagnoses were not recorded as 
part of the current study, considering the recruitment setting (acute inpatient treatment and 28-
day residential treatment programs), it is possible that participants may receive psychiatric 
medication interventions where the medication can be used in a suicide attempt (Bohnert & 
Ilgen, 2019).  
Individuals in the SI/SA group had higher ACE scores and were more likely to have 
experienced physical abuse or teen dating violence before the age of 18, which is consistent with 
previous research (Hakansson et al., 2006; Roy, 2002; Darke et al, 2012). While previous 
research has demonstrated a connection between childhood sexual abuse and the risk of overdose 
among individuals with OUD (Molnar et al., 2001; Roy, 2002), interestingly our study found that 
sexual abuse in the past year more strongly associated with unintentional overdose. These 
patterns of abuse both inside and outside the home could be associated with low levels of family 
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support, high levels of hopelessness, and perpetuating cycles of depression and hopelessness that 
contribute to resulting suicidal behaviors (Bradvik et al., 2007; Chen et al., 2009). 
Moreover, self-injurious behaviors are one of the most important risk factors for future 
suicide and are often even more predictive than a history of suicidal ideation (Cavanagh et 
al.,2003). As seen with previous research (Darke et al., 2012), this study found that the mean age 
of onset for SIB (14 years old) preceded the mean age of onset of suicidal ideation (21 years 
old). Most research reports first SIB in early adolescence (Maloney et al., 2010) while this was 
true for the unintentional overdose group, the SI/SA and SI/SA/OD groups had mean age of 
onset of SIB occurring later at age 16.7 and 16.9 respectively. Furthermore, more individuals in 
the SI/SA group engaged in SIBs in the past month compared to either the SI/SA/OD group or 
the unintentional OD group where no participants reported any SIBs in the past month. While 
these results were not statistically significant, they are clinically meaningful in that participants 
engaging in SIB also reported suicidal behaviors more frequently than those without any SIBs in 
the prior month. 
Limitations 
 
We acknowledge this study has several limitations. First, despite specification of opioid 
overdose as “decreased respiratory depression,” subjects reported non-opioid related overdoses. 
Lifetime suicidal ideation was assessed using retrospective self-reporting and recall bias may be 
problematic. Recall bias could have also influenced reporting of substances used in the 24-hours 
prior to the most recent overdose, since the time period between interview and date of the 
subject’s last overdose was variable. Additionally, length of stay and healthcare utilization were 
not measured in the current study. This limited our ability to examine or extrapolate any causal 
relationships between past 30-day substance use with outcome behaviors such as overdose, 
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suicide attempt, suicidal ideation, and self-injurious behaviors. Likewise, the sample size was 
small limiting this study to be conducted as exploratory research and hence the power to detect 
group differences was not calculated. Our sample was predominantly white and included 
residents residing in a non-urban Appalachian area, which may limit generalizability regarding 
different demographic groups and subjects receiving outpatient OUD treatment.  
Future Research  
There are several future directions suggested by this research. First, the results such more 
in-depth investigation of overdose typologies that differentiate overdose intentionality and 
specification of substances used. Prospective studies are needed to understand causality and 
model the dynamics of intentionality, as well as account for how impulsivity may moderate the 
association. Moreover, unintentional overdoses and suicidal behaviors were found to be 
associated with wish to live and SIB. These results have the potential to inform clinical 
interventions and harm reduction strategies as it may help identify intentionality. These patients 
may utilize multiple methods for suicide attempts further complicating the determination of 
overdose intentionality. This issue warrants further investigation not only from an intentionality 
perspective, but also to develop more effective harm reduction strategies.  
4.6 Conclusions 
Results from this study partially elucidated differences clinical and behavioral differences 
between OUD patients with a history of unintentional overdose versus suicidal ideation/attempt. 
Whereas, subjects with a history of SI/SA/OD represent a diverse group with potentially greater 
severity that would likely benefit from multimodal intervention. Despite, differences in 
substance use that distinguish intentional from unintentional overdoses, future research needs to 
focus on systematically addressing overdose typologies. Overall, this study highlights the 
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importance of addressing the contribution of history of self-injury, types of substances used the 
day of overdose, recent life stressors, and adverse childhood experiences for both overdose and 
suicide among patients with opioid use disorders. 
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Table 4.1: Overdose History and Substance Use Associated with Recent Overdose 








Characteristics      
Mean number substances used (Past 30 days), 
(SD)† 2.5 (1.5) 2.2 (2.0) 2.5 (1.2) 2.7 (1.7) 0.64 
Ever Inject Drugs (%Yes, Lifetime) 75.8 84.6 66.7 85.0 0.26 
Mean Age First IDU (SD)+ 24.9 (9.2) 23.5 (8.5) 24.5 (9.0 26.3 (10.1) 0.72 
Median Number Overdoses 3.0 3.0 3.0 1.5 0.71 
Mean Age First Overdose (SD)+ 27.4 (11.0) 29.9 (11.8) 25.7 (9.9) 26.7 (11.5) 0.54 
Substances Used 24 hours Prior to OD (% Yes)      
      Alcohol  20.0 23.1 18.8 20.0 0.92 
      Antidepressants 10.9 7.7 23.1 5.0 0.36 
      Antipsychotics 10.9 7.7 30.7 0.0 0.02 
      Benzodiazepines 21.7 23.1 15.4 25.0 0.90 
      Cocaine 13.0 7.7 0.0 25.0 0.15 
      Prescription Opioids 19.6 15.4 23.1 20.0 1.00 
      Heroin 67.4 92.3 30.7 75.0 <0.01 
      Methamphetamine 15.2 23.1 7.7 15.0 0.69 
      Sedatives 2.2 0.0 0.0 5.0 1.00 
Naloxone to reverse (% Yes) 52.4 76.9 41.7 41.2 0.11 
1Unintentional Overdose= patients who self-reported only unintentional overdoses. 
2SI/SA= patients who self-reported any of the following: 1) suicide attempt only, 2) intentional overdose only, 3) suicidal ideation and suicide attempt, 4) 
suicidal ideation and intentional overdose, 5) suicide attempt and intentional overdose, or 6) intentional overdose, suicidal ideation, and suicide attempt. 
3SI/SA/OD= patients who self-reported any of the following: 1) suicidal ideation, 2) suicidal ideation and intentional overdose, 3) suicide attempt and 
unintentional overdose, or unintentional overdose, suicidal ideation, and suicide attempt. 
Abbreviations: IDU=Injection drug use; OD=overdose; SA= suicide attempt; SD= standard deviation; SI= suicidal ideation 
+All ages noted with “+” were noted as means for ease of comparison, but nonparametric statistics were used for comparison as these samples did not 
follow a normal distribution.  





































ACE Domains (% Yes)      
Mental Health Problems  63.6 38.5 75.8 60.0 0.06 
Alcohol or Drug Use  77.3 61.5 81.8 80.0 0.37 
Emotional Abuse  71.2 46.2 75.8 80.0 0.09 
Physical Abuse  81.8 46.2 93.9 85.0 <0.01 
Teen Dating Violence*  81.8 46.2 93.9 85.0 <0.01 
Sexual Abuse  51.5 38.5 63.6 40.0 0.17 
Neglect  93.9 100.0 97.0 85.0 0.12 
Family Dissolution  65.2 69.2 69.7 55.0 0.52 
Total mean ACE domain score (SD) 5.0 (1.7) 4.0 (1.7) 5.5 (1.4) 5.0 (1.9) 0.04 
Total mean LEC score (SD) 11.7 (8.5) 10.8 (6.9) 11.7 (8.3) 12.1 (10.0) 0.90 
1Unintentional Overdose= patients who self-reported only unintentional overdoses. 
2SI/SA= patients who self-reported any of the following: 1) suicide attempt only, 2) intentional overdose only, 3) suicidal ideation and suicide attempt, 
4) suicidal ideation and intentional overdose, 5) suicide attempt and intentional overdose, or 6) intentional overdose, suicidal ideation, and suicide 
attempt. 
3SI/SA/OD= patients who self-reported any of the following: 1) suicidal ideation, 2) suicidal ideation and intentional overdose, 3) suicide attempt and 
unintentional overdose, or unintentional overdose, suicidal ideation, and suicide attempt. 
*Define as physical or emotional abuse experienced by a significant other before the age of 18 years old.  























































Table 4.3: Measures of Ambivalence and Self-Injurious Behavior (SIB) 







Wish to live     0.02 
    Moderate/Strong 71.2 100.0 63.6 65.0  
    Weak/None 28.3 0.0 36.4 35.0  
Life Threatening Situation     0.71 
    Would try to save my life 60.6 76.9 54.6 60.0  
    Would take a chance on life/death 30.3 23.1 33.3 30.0  
    Would not avoid death 9.1 0.0 12.1 10.0  
History of SIB (% Yes) 37.9 23.1 42.4 40.0 0.56 
Mean age first SIB+ 16.4 (6.8) 14.0 (1.0) 16.7 (8.3) 16.9 (5.4) 0.66 
Median lifetime episodes SIB 15.0 20.0 45.0 5.0 0.05 
Last occurrence of SIB     0.73 
    In past month 28.0 0.0 35.7 25.0  
    Past 2-12 months 40.0 33.3 42.9 37.5  
    More than a year ago 32.0 66.7 21.4 37.5  
SIB Behaviors (% Yes)      
   Cutting 33.9 15.4 40.6 35.0 0.30 
   Hitting oneself on purpose 30.8 7.7 40.6 30.0 0.08 
   Hair pulling 18.5 7.7 28.1 10.0 0.22 
   Self-tattooing 13.9 7.7 15.6 15.0 0.90 
   Picked a wound 21.5 7.7 31.3 15.0 0.20 
   Burning 15.4 7.7 21.9 10.0 0.48 
   Inserted objects under nails or skin 4.6 0.0 9.4 0.0 0.30 
   Biting 9.2 0.0 15.6 5.0 0.32 
   Picked areas of body to point of drawing blood 13.9 0.0 18.8 15.0 0.32 
   Scraped skin 10.8 0.0 15.6 10.0 0.38 
   “Erased” skin to the point of drawing blood 6.2 0.0 6.3 10.0 0.66 
Received medical treatment for SIB (% Yes) 40.0 33.3 42.9 37.5 1.00 
1Unintentional Overdose= patients who self-reported only unintentional overdoses. 
2SI/SA= patients who self-reported any of the following: 1) suicide attempt only, 2) intentional overdose only, 3) suicidal ideation and suicide 
attempt, 4) suicidal ideation and intentional overdose, 5) suicide attempt and intentional overdose, or 6) intentional overdose, suicidal ideation, and 
suicide attempt. 
3SI/SA/OD= patients who self-reported any of the following: 1) suicidal ideation, 2) suicidal ideation and intentional overdose, 3) suicide attempt 
and unintentional overdose, or unintentional overdose, suicidal ideation, and suicide attempt. 
Abbreviations: IDU=Injection drug use; OD=overdose; SA= suicide attempt; SD= standard deviation; SI= suicidal ideation 
All ages noted with “+” were noted as means for ease of comparison, but nonparametric statistics were used for comparison as these samples 































Mean Age first suicidal ideation (SD)+ 21.0 (12.2) 23.3 (11.9) 20.6 (13.5) 20.8 (10.1) 0.64 
Median episodes suicidal ideation 10.0 7.0 15.0 10.0 0.45 
Last occurrence of suicidal ideation     0.02 
    In the past month 82.7 16.7 90.9 68.4  
    Past 2-12 months 9.6 33.3 9.1 10.5  
    More than one year ago 7.7 50.0 0.0 21.1  
Suicide Attempt(s) (% Yes)     <0.01 
     Never 28.8 100.0 9.1 15.0  
     Brief, passing thought 10.6  12.1 15.0  
     I had a plan once, but did not try 6.1  6.1 10.0  
     I had a plan once, and really wanted to die 0.0  0.0 0.0  
     I have attempted to kill myself, but did not want to die 6.1  3.0 15.0  
     I have attempted to kill myself, and really hoped to die 48.5  69.7 45.0  
Frequency of Suicidal Ideation (% Yes)     0.55 
    Never/Rarely 7.5  3.9 14.3  
    Sometimes 7.5  3.9 7.1  
   Often/Very Often 85.0  88.5 78.6  
Disclosure of Suicide Attempt (% Yes)     0.91 
    No 50.0  53.9 42.9  
    Yes, at one time, but did not want to die 5.0  3.9 7.1  
    Yes, at one time, and really wanted to die 12.5  11.5 14.3  
    Yes, more than once, but did not want to die 2.5  3.9 0.0  
    Yes, more than once, and really wanted to die 30.0  26.9 35.7  
Likelihood of future suicide attempt (% Yes)     0.23 
   Never/No Chance 32.5  30.8 35.7  
   Unlikely 37.5  30.8 50.0  
   Likely 15.0  15.4 14.3  
   Very Likely 15.0  23.1 0.0  
Mean Suicide Behaviors Questionnaire (SBQ-R) Total Score+ 8.2 (6.1)  10.8 (5.5) 8.7 (5.5) 0.15 
1Unintentional Overdose= patients who self-reported only unintentional overdoses. 
2SI/SA= patients who self-reported any of the following: 1) suicide attempt only, 2) intentional overdose only, 3) suicidal ideation and suicide 
attempt, 4) suicidal ideation and intentional overdose, 5) suicide attempt and intentional overdose, or 6) intentional overdose, suicidal ideation, and 
suicide attempt. 
3SI/SA/OD= patients who self-reported any of the following: 1) suicidal ideation, 2) suicidal ideation and intentional overdose, 3) suicide attempt 
and unintentional overdose, or unintentional overdose, suicidal ideation, and suicide attempt. 
Abbreviations: IDU=Injection drug use; OD=overdose; SA= suicide attempt; SD= standard deviation; SI= suicidal ideation 
All ages noted with “+” were noted as means for ease of comparison, but nonparametric statistics were used for comparison as these samples 
did not follow a normal distribution. 
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Table 4.5: Multivariable Regression Model  
 Unadjusted Analyses 
 Unintentional OD SI/SA/OD 
Variable Coefficient 95 % CI p-value Coefficient 95 % CI p-value 
ACE total domain score -0.5 -1.1, -0.01 0.05 -0.4 -0.9, 0.1 0.15 
Work accident (past year) -15.1 -18.3, -17.2 <0.01 2.1 0.3, 3.9 0.02 
Sexual assault (past year) -19.2 -21.2, -17.2 <0.01 -0.9 -2.9, 1.1 0.38 
Combat exposure (past year) -18.2 -21.6, -14.9 <0.01 -18.2 -21.1, -15.3 <0.01 
Hitting 0.4 -2.1, 2.9 0.74 -0.2 -2.0, 1.6 0.9 
Depression (past two weeks) -0.4 -3.4, 2.5 0.78 -0.8 -4.0, 2.4 0.6 
Hopelessness (past two weeks) -3.0 -5.9, -0.2 0.03 -0.2 -2.6, 2.3 0.9 
 Adjusted Analyses 
 Unintentional OD SI/SA/OD 
Variable Coefficient 95 % CI p-value Coefficient 95 % CI p-value 
Age -0.1 -0.2, 0.03 0.15 -0.1 -0.2, -0.01 0.02 
Sex -0.7 -2.5, 1.1 0.43 -0.1 -1.6, 1.3 0.87 
ACE total domain score -0.6 -1.2, -0.1 0.03 -0.5 -1.03, 0.06 0.08 
Work accident (past year) -13.8 -17.0, -10.7 <0.01 2.1 0.3, 3.9 0.02 
Sexual assault (past year) -17.0 -19.6, -14.5 <0.01 -0.7 -2.6, 1.2 0.45 
Combat exposure (past year) -15.1 -20.3, -9.9 <0.01 -16.7 -19.2, -14.1 <0.01 
Hitting -1.2 -5.3, 2.8 0.56 -0.5 -2.2, 1.2 0.54 
Depression (past two weeks) -1.3 -4.5, 1.9 0.43 -1.5 -5.4, 2.5 0.47 
Hopelessness (past two weeks) -1.6 -4.4, 1.2 0.27 -0.6 -3.7, 2.4 0.69 
Global social support score -0.2 -1.7, 1.2 0.75 -0.6 -2.2, 0.9 0.42 
Base Outcome: SI/SA= Suicidal Ideation & Suicide Attempt 
Abbreviations: ACE= adverse childhood experiences; CI=confidence interval; LEC=life events checklist; OD= overdose; SA=suicide attempt; 
SIB=self-injurious behavior; SI=suicidal ideation;SI/SA/OD= patients who self-reported any of the following: 1) suicidal ideation, 2) suicidal 



























5 Discussion of Findings and Research Implications 
5.1 Summary 
The literature review presented in this study is the first to include self-injurious behaviors to 
evaluate the relationship between suicide, overdose, and OUD.  Results from this review 
provided the foundation for implementation of patient safety screening for overdose and suicide 
history in addiction treatment facilities.  The mPSS is potentially the first screening tool to 
simultaneously assess suicide risk and overdose in these setting.  Additionally, the brevity of the 
mPSS increases the probability of integration in routine clinical practice.  Results from initial 
implementation of these screening procedures indicates that persistence of non-fatal SIB needs 
continued assessment over the course of the lifespan, paying attention to how these behaviors 
may evolve in adulthood.  Furthermore, traumatic childhood events and past year stressful 
experiences are important in SIB assessment.  Future research needs to address comprehensive 
discharge planning and risk management for both suicide and overdose.  This includes provision 
of global social support, acute and long-term crisis management, and trauma informed care.  
5.2 Strengths and Limitations 
5.2.1 Strengths 
Strengths of this study are that it includes the first systematic review to focus on self-
injurious behavior, overdose, and suicidal behaviors.  While several systematic reviews have 
studied these relationships to varying degrees in the past, this review is the first to examine 
literature that reports on overdose and SIB simultaneously.  Additionally, this review examines 
precursory behaviors to suicide and overdose among individuals with a specific focus on OUD.  
This literature review was further used to inform a feasibility and acceptability study of the first 
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standardized tool for universal suicide and overdose screening for patients receiving addiction 
treatment services. Although, suicide screening and assessment is usually a part of standard 
mental healthcare procedures, behavioral health practices do not consistently evaluate additional 
self-harm and overdose behaviors.  This study provided a standardized tool that could be 
integrated into clinical framework and address these aspects with one instrument.  Finally, 
through examination of subjects who screened positive on the mPSS, patients could be separated 
into three distinct clinical groups: 1) unintentional overdose only, 2) suicidal ideation/suicide 
attempt, and 3) unintentional overdose/suicidal ideation/suicide attempt.  This allowed for 
preliminary investigation of clinical and behavioral characteristics that may provide more insight 
for distinguish intentional and unintentional overdose.  Elucidating these factors would 
ultimately have implications for treatment planning and risk reduction.  
5.2.2 Limitations 
This study has some potential limitations. In conducting the systematic review, the majority 
of studies was cross-sectional. Thus, temporal conclusions could not be drawn that linked onset 
of OUD with SIB, suicidal ideation, and/or attempted suicide. A large portion of the available 
data relied on self-report measures for attempted suicide history, overdose history, and some 
clinical data. Therefore, recall bias was a predominant research limitation. Furthermore, there is 
limited generalizability of the studies conducted among inpatient or outpatient treatment 
samples.  Unknown is whether treatment seeking individuals have more functional impairments 
or experience more symptom severity than non-treatment seeking individuals.   
Additionally, several limitations are associated with the studies conducted among patients 
receiving addiction treatment services. Recruiting subjects from an inpatient population may 
limit whether these results can be generalized to patients seeking treatment services in other 
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settings.  The majority of the subjects recruited for this study was predominantly white and non-
Hispanic, which may not generalize to other ethnic and demographic groups. All assessments 
were administered by members of the study team.  However, in order to integrate these tools into 
clinical practice, members of the clinical team would need to administer the screening to patients 
or have patients self-administer the tool. This may require more individualized time from the 
staff, and increased cooperation from patients that could increase the burden on both patients and 
staff. To avoid the confounding effects of acute intoxication on our results, patients were not 
interviewed for at least 24-hours after admission.  However, this cautionary measure may not be 
practical in all treatment settings. Likewise, despite specification of overdose as “decreased 
respiratory depression,” subjects reported non-opioid related overdoses. Lifetime suicidal 
ideation, overdose(s), and suicide attempt(s) were retrospectively self-reported, and thus recall 
bias may be a potential limitation.   
5.6 Conclusions and Implications 
The relationship between self-injurious behaviors, suicidal ideation, suicide planning, and 
suicide attempt has been investigated to varying degrees throughout the published literature. 
Individuals with these behaviors demonstrate decreased social function, psychiatric decline, and 
more severe substance.  This finding provides crucial information for potential clinical 
intervention, treatment, and crisis management. However, there is still a lack of prospective 
longitudinal data that provide adequate temporal information between onset of OUD, SIB and/or 
suicide outcomes. Previous literature has found that patients with OUD at highest risk of 
attempted suicide and SIB tended to have more severe psychiatric profiles, be female, have 
increased rates of poly-drug use, and experienced significant life stressors and childhood 
maltreatment. In this study, 60% of patients screened positive on the mPSS, with 86% of subjects 
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screening positive on more than one factor.  Further assessment found that approximately 20% of 
subjects experienced an unintentional overdose with no suicidal ideation, and 30% of the sample 
experienced all three events: an unintentional overdose, suicidal ideation, and at least one suicide 
attempt during their lifetime.  Results from this study appear to be the most compelling between 
the unintentional overdose and suicidal ideation/suicide attempt group.  Differences most 
commonly related to a history of lifetime substance use, substances used in the 24-hours prior to 
overdose, physical or emotional abuse during childhood, and frequency of lifetime SIB.  
Overall, this study highlights the importance of addressing the contribution of history of 
self-injury, types of substances used the day of overdose, and ACEs for both overdose and 
suicide among patients with OUD.  These patients may engage in a range of high-risk behaviors 
that further complicate developing effective risk reduction strategies and effective discharge 
planning.  While there are distinctive characteristics between individuals that have unintentional 
overdoses only and individuals with suicidal ideation/suicide attempts without history of 
overdose; patients with a history of all three events may complicate the overall picture and 
require more complex clinical interventions. Despite, differences in substance use that 
distinguish intentional from unintentional overdoses, future research needs to focus on 
systematically addressing substance typologies in overdose.  However, additional research is 
needed to determine whether screening improves the provision of services and reduces future 
associated self-injurious behavior.  In general, the greater the burden of risk factors, the higher 
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7.2 Supplemental Figure (Chapter 3): Modified Patient Safety Screen 
 
Modified Patient Safety Screener 
 
1. Over the past 2 weeks, have you felt down, depressed, or hopeless? 
        
                 Yes             No        Patient unable to complete        Patient refused 
2. Over the past 2 weeks, have you have you had thoughts of killing yourself? 
            
                  Yes             No        Patient unable to complete        Patient refused 
3. In your lifetime, have you attempted to kill yourself? 
           
              Yes                No       Patient unable to complete       Patient refused  
            3a. When did his happen? 
          
               Within the past 24 hours      Within the past month (not including today)      In the past 1-6 months 
 
             More than 6 months ago      Patient unable to complete       Patient refused 
4. In your lifetime, have you ever overdosed? 
            
              Yes         No        Patient unable to complete        Patient refused 
             4a. When did this happen? 
          
               Within the past 24 hours      Within the past month (not including today)      In the past 1-6 months 
 













7.3 Supplemental Figure (Chapter 3) 














































Characteristics      
Mean Age (years), (SD) 36.1 (9.5) 36.1 (9.3) 37.3 (9.6) 34.1 (9.7) 0.47 
Sex (Male) 65.2 69.2 63.6 65.0 1.00 
White  93.4 100.0 93.9 90.0 0.66 
Non-Hispanic  93.4 100.0 90.9 95.0 0.81 
Employed  25.8 23.1 21.2 35.0 0.57 
Education      0.68 
     Less than High School 19.7 23.1 24.2 10.0  
     High School Grad/GED 50.0 46.2 51.5 50.0  
     Some College/College Grad 30.3 30.8 24.2 40.0  
Lifetime Arrests (Median) 5 3 3 6 0.88 
Lifetime Substance Use (% Yes)      
     Tobacco 98.5 100.0 97.0 100.00 1.00 
      Alcohol 100.0 100.0 100.0 100.0 - 
     Cocaine 84.9 100.0 72.3 95.0 0.02 
     Marijuana 97.0 100.0 97.0 95.0 1.00 
     Heroin 87.9 92.3 81.8 95.00 0.43 
     Prescription Opioids 89.4 69.2 97.0 90.0 0.03 
     Buprenorphine to get high 39.4 38.5 39.5 40.0 1.00 
    
Methamphetamines/Amphetamines 
87.9 84.6 87.9 90.0 1.00 
     Benzodiazepines 69.7 69.2 69.7 70.0 1.00 
Mean age of Initiation of Substance 
Use (Years), (SD) 
     
     Tobacco+ 13.1 (5.5) 13.4 (4.0) 13.2 (6.7) 12.8 (4.1) 0.92 
      Alcohol+ 13.8 (8.7) 12.5 (3.9) 15.1 (11.4) 12.7 (4.6) 0.55 
     Cocaine+ 18.7 (5.4) 20.7 (6.1) 18.0 (6.1) 18.2 (3.8) 0.42 
     Marijuana+ 14.5 (4.5) 14.5 (3.0) 15.1 (5.5) 13.4 (3.4) 0.47 
     Heroin+ 24.7 (9.8) 26.4 (12.6) 25.0 (9.2) 23.2 (9.1) 0.74 
     Prescription Opioids+ 18.4 (7.4) 17.3 (5.5) 19.1 (7.7) 17.8 (7.9) 0.41 
     Illicit use of Buprenorphine  25.6 (10.6) 23.6 (10.7) 25.5 (9.6) 26.9 (13.1) 0.87 
     
Methamphetamines/Amphetamines+ 
26.6 (8.9) 29.5 (9.4) 24.9 (8.3) 27.8 (9.4) 0.31 
     Benzodiazepines 21.4 (9.3) 19.8 (7.9) 22.5 (10.4) 20.5 (8.6) 0.79 
Mean number substances used  
(Past 30 days), (SD) 2.5 (1.5) 2.2 (2.0) 2.5 (1.2) 2.7 (1.7) 0.64 
Ever Inject Drugs (%Yes, Lifetime) 75.8 84.6 66.7 85.0 0.26 
Mean Age First IDU (SD)+ 24.9 (9.2) 23.5 (8.5) 24.5 (9.0 26.3 (10.1) 0.72 
1Unintentional Overdose= patients who self-reported only unintentional overdoses. 
2SI/SA= patients who self-reported any of the following: 1) suicide attempt only, 2) intentional overdose only, 3) suicidal 
ideation and suicide attempt, 4) suicidal ideation and intentional overdose, 5) suicide attempt and intentional overdose, or 6) 
intentional overdose, suicidal ideation, and suicide attempt. 
3SI/SA/OD= patients who self-reported any of the following: 1) suicidal ideation, 2) suicidal ideation and intentional overdose, 3) 
suicide attempt and unintentional overdose, or unintentional overdose, suicidal ideation, and suicide attempt. 
Abbreviations: IDU=Injection drug use; OD=overdose; OTC=over the counter; SA= suicide attempt; SD= standard deviation; 
SI= suicidal ideation 
+All ages noted with “+” were noted as means for ease of comparison, but nonparametric statistics were used for comparison 
as these samples did not follow a normal distribution.  
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7.5 Supplemental Table Chapter 4: Not Included in Analysis 










Past Year Event (% Yes)      
Relationship Dissolution 59.1 86.6 60.6 40.0 0.04 
Natural Disaster 4.6 0.0 6.1 5.0 1.0 
Fire 7.6 7.7 3.0 15.0 0.27 
Work Accident 4.6 0.0 6.1 5.0 1.0 
Car Accident 13.6 7.7 9.1 25.0 0.23 
Exposure to Toxic Substance 18.2 15.4 18.2 20.0 1.0 
Physical Assault 37.9 30.8 36.4 45.0 0.75 
Assault with a Weapon 13.6 7.7 15.2 15.0 0.90 
Sexual Assault 10.6 0.0 15.2 10.0 0.38 
Unwanted Sexual Experiences 15.2 7.7 18.2 15.0 0.90 
Combat Exposure - - - - - 
Captivity 15.2 7.7 12.1 25.0 0.42 
Severe Suffering 34.9 30.8 27.3 50.0 0.26 
Violent Death (witnessed) 4.6 0.0 6.1 5.0 1.0 
Unexpected Death (witnessed) 15.2 15.4 21.1 5.0 0.35 
Caused Harm or Death 7.6 0.0 9.1 10.0 0.70 
Illness 34.9 38.5 27.3 45.0 0.38 
Misc. Stressful Experiences 50.0 69.2 48.5 40.0 0.28 
Supplemental Table: Response variables were recoded to yes or no. “Yes,” was defined as having experienced or witnessed any of the 
events listed on the life events check list. All other responses were coded as “No.” This was done due to small sample size and overall 
distribution of response rates. 
 
